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The identification of alternative cell death pathways is an urgent necessity to overcome 
chemoresistance. In fact, the high prevalence of intrinsic and acquired apoptotic resistance, of 
cancer cells, to the pro-apoptotic drugs represents one of the main causes of chemotherapeutic 
failure. Among novel therapeutic targets, the deubiquitinating enzymes (DUBs) are intriguing 
and promising. Specifically, G5, a cell-permeable cross-conjugated unsaturated dienone, by 
inhibiting some DUBs, induces proteotoxic stress, and a peculiar largely unexplored necrotic 
response. In this context, to better dissect the components involved in the transducing G5-
elicited cell death, two strategies have been followed: I) a proteomic approach to map the 
cellular targets using a G5-derivate (2c) for pull-down, and II) an unbiased genome screening 
to identify the key genes controlling G5-induced necrotic response. 
Proteomic profiling was performed using a biotin-conjugated diaryldienone-derivative named 
2c-Biotin, as a bait to purify the intracellular targets of this small molecule. The spectrum of 
proteins recognized by 2c-Biotin was quite large, showing a certain affinity for isopeptidases, 
but surprisingly, also for different proteins, such as Akt and Cofilin-1. The plethora of targets 
bound by G5 can elicit multiple stresses, thus explaining the efficient anti-tumor activity of 
these inhibitors observed in vivo. Moreover, a PEG-conjugated version of 2c was tested in 
leukemia cells to further study the transcriptional programs engaged by this inhibitor and to 
verify the possibility to use this inhibitor in clinic.  
The short hairpin RNA screen strategy was used in U87MG glioblastoma cells, which were 
chosen for their apoptosis resistance and propensity to die by necrosis. The transduction of 
pooled library of 27500 shRNAs, and the selection of clones resistant to G5 treatment, 
allowed the identification of pro-death proteins. Among them, glycogen synthase kinase-3 β 
(GSK3β) was further investigated. U87MG cells knocked-out for GSK3β were generated by 
using the CRISPR/Cas9 system. The response of U87MG/GSK3β-/- cells to the treatment with 
two specific necrotic stressors, G5 and the redox cycling agent 2,3-Dimethoxy-1,4-
naphthoquinone (DMNQ), showed that this kinase plays a main pro-death role in the ROS-
induced necrosis generated by DMNQ, and a minor role during G5-induced necrosis. An early 
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and strong activation of GSK3β was reveled, upon DMNQ treatment, which in turn controls 
and modulates the integrity and functionality of mitochondria in the treated cells.   
By a time lapse analysis, we demonstrated that GSK3β, in the U87MG/GSK3β-/- re-expressing 
GSK3β-GFP cells, translocates in the nucleus during the later steps of DMNQ treatment, but 
before Δψm collapse. Our results point out the essential role of GSK3β in the triggering the 
oxidative stress-dependent necrotic response. Nevertheless, further analysis are required to 
better investigate which substrates are involved in the GSK3β-mediated death/life balance 
control and which effects the kinase exerts in the nucleus.  
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1. Introduction  
1.1 The ubiquitin-proteasome system (UPS) 
1.1.1 The ubiquitylation process: components and cellular “meaning” 
Cells have different strategies to control the protein status on the basis of the different extra- 
and intracellular signals. Alterations on transcriptome is a way to respond to the 
environmental changes, even if the post-translational modifications of the proteome provide a 
faster way to activate or to inhibit different signaling pathways. An alternative mechanism to 
regulate proteins levels is provided by their degradation, an irreversible strategy to switch off 
a particular pathway (Pickart, 2004; Wilkinson, 2004; Hershko et al., 2000).          
In eukaryotic cells, one of the major responsible for the degradation of cellular proteins is the 
ubiquitin-proteasome system (UPS) (Chiechanover, 2005). The UPS-mediated protein 
degradation plays an essential role in a wide number of cellular processes, such as: cell-cycle 
progression, gene expression, differentiation and cell death. In fact, an abnormal regulation of 
this system can contribute to the onset of different pathological conditions, including tumor 
formation, autoimmunity and neurodegenerative diseases (Demarchi and Brancolini, 2005).  
Generally, all cellular proteins are degraded to amino acids and replaced by newly synthesized 
proteins. The half-life of each protein is different, ranging from few minutes up to different 
days. A specific step for protein degradation is their labeling with a molecule called ubiquitin 
(Ub), through an energy-requiring process. The poly-ubiquitination represents the process by 
which this addressing signal is linked to target proteins for their digestion into smaller 
peptides through the proteolytic complex known as 26S proteasome. The importance of the 
UPS is testified by its involvement in the physiological protein turnover and in the protein 
quality-control. The UPS is critical to remove damaged or misfolded proteins that can 
interfere negatively with the cellular functions and viability (Goldberg and Dice, 1974; 
Sherman and Goldberg, 2001; Goldberg, 1972).  
 6
Introduction
When a protein has to be degraded, it is marked with a chain of linked molecules of Ub. Ub is 
a small 76 amino acid polypeptide, highly conserved through the evolution, used to influence 
protein activities, interactions, stability and localization (Vijay-Kumar et al., 1987; Hershko et 
al., 1983). Generally, an isopeptide linkage (-CO-NH2ε-) between a lysine residue of the 
protein target and the C-terminal glycine residue (G76) of Ub is involved in the conjugation 
process. This first Ub molecule can be next used to form a chain via additional linkages 
between one of the seven lysine residues present on itself and other Ub molecules. In this 
way, the target proteins can be mono-ubiquitylated, multi-monoubiquitylated or poly-
ubiquitylated (Fig.1). Specifically, the Ub sequence presents the following lysine residues: 
K6, K11, K27, K29, K33, K48 and K63, which are available for the conjugation. The 
common Lys involved in protein degradation is the lysine-48 (K48). However, some findings 
reported that also homogenous poly-ubiquitin chains assembled through the lysine-63 (K63) 
are able to target the proteins to the proteasome (Saeki et al., 2009). In addition to the poly-
ubiquitin chains, described as the minimal proteasomal targeting signal (Thrower et al., 2000), 
proteins conjugated with a single Ub moiety (mono-ubiquitylated) and multiple single 
moieties (multiple mono-ubiquitylated) can be recognized by the proteasome (Kim et al., 
2007).   
When an Ub-tagged protein is recognized by the proteasome, it is degraded into small 
peptides and Ub molecules are recycled (Chau et al., 1989; Gregori et al., 1990; Pickart, 
2000). Furthermore, target proteins,  linked by multiply branched (“forked”) chains, in which 
two or more Ub molecules are linked to a single Ub molecule, cannot be processed by the 
proteasome, but they can play different roles in non-proteolytic regulatory processes, such as 
DNA repair, assembly of signaling complexes, endocytosis, intracellular trafficking and 
transcriptional regulation (Kim et al., 2007; Muratani and Tansey, 2003; Jesenberger and 
Jentsch, 2002; Jackson and Durocher, 2013). Not surprisingly, misregulation of the Ub system 
can be linked with severe pathological conditions, such as cancer, some types of mental 
retardation and neurodegenerative disorders (Parkinson’s disease, Huntington’s disease and 
Alzheimer’s disease) (Schwartz and Chiechanover, 2009). 
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Ub itself assumes a compact structure with a hydrophobic core given by 3 hydrophobic 
residues of ɑ-helix and 11 hydrophobic residues of β-sheet (Vijay-Kumar et al., 1987). Sheet 
structure “grasps” around the ɑ-helix, forming a β-grasp fold. Some areas of this structure 
represent the center of the most known interactions with the proteins containing Ub-binding 
domain (UBD) (Dikic et al., 2009). The formation of non-covalent interactions, between the 
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Fig.1: Complexity of Ub and UbL chains. (A) Seven lysine residues in a single Ub molecule. (B) 
Homogenous chains in which Ub moiety is linked to the next one through the same lys residue. (C) 
An example of free poly-ubiquitin chain. (D) Heterogeneous Ub chains in which the links between 
the Ub molecules involved different internal lysine residues. These chains can be singly branched 
(each Ub moiety is linked with a single Ub; E) or multiply branched (each Ub moiety is linked with 
two or more Ub moieties by different internal lysine residues; F). (G) An example of linear Ub chain. 
(H) Modification by a single Ub moiety. (I) Modification by multiple single Ub moieties. (J) 
Modification of “non -canonical” residues in the target protein. (K) N-terminal residue modification 
of the substrate. (L) Mono or poly-modification of the substrate by an UbL chain. (M) Modification 
of the substrate by a mixed chain of UbL and Ub molecules (Chiechanover and Stanhill, 2014).
Introduction
Ub hydrophobic area and the UBD of different interacting proteins, mediates the effects of the 
ubiquitylation process. Numerous UBDs have been found in some subunits of the proteasome. 
UBD containing proteins are also involved in DNA repair and endocytosis (Komander et al., 
2009; Kodadek, 2010).  
Similarly to Ub, Ub-like proteins (UbLs) are conjugated to various proteins or other 
molecules (Fig.1). Among these UbLs, the most studied are the interferon-stimulated gene 
product of 15 kDa ISG15 (Haas et al., 1987), the small ubiquitin-related modifier SUMO 
(Kerscher et al., 2006) and the neural precious cell-expressed developmentally downregulated 
protein 8 NEDD8.  
Ub and UbLs conjugation process is provided by an enzymatic cascade involving E1 
ubiquitin-activating enzymes (Schulman and Harper, 2009), E2 ubiquitin-conjugation 
enzymes (Ye and Rape, 2009) and E3 ubiquitin ligases (Buetow and Huang, 2016). The first 
class of enzymes hydrolyses ATP and adenylates the C-terminal Gly residue of a single Ub 
molecule, then this residue is linked to the active site of one E1 enzyme. Next, the thioester-
linked Ub molecule is transferred to the cysteine residue of one E2 ubiquitin-conjugating 
enzyme through a thiol ester bond. Different enzymes are involved in the activation of UbL 
molecules: E1SUMO for SUMO, E1NEDD8 for NEDD8 and E1ISG15 for ISG15. These 
UbLs E1 enzymes are able to act on their respective E2 Ub-conjugating enzyme C9 (UBC9), 
UBC12 and UBC8 (Schwart and Hochstrasser, 2003).  
E3 Ub ligases represent the most heterogeneous class of enzymes. In fact, the human genome 
contains two E1s, approximately 38 E2s and more than 600 E3s (Jin et al., 2007; Ye and 
Rape, 2009). The E3 enzymatic class can be subdivided in three subfamily (RING, HECT and 
RBR E3s) on the base of the containing enzymatic domains and of the mechanism by which 
the Ub is transferred (Morreale and Walden, 2016). Moreover, this last step confers specificity 
to the entire ubiquitylation process, defining in this way the final destination of each cellular 
protein. A comprehensive proteomic study reported tens-of-thousands ubiquitination sites 
detected on an equally number of proteins within a cell, demonstrating the strong impact of 
the Ub system on the cellular life (Peng et al., 2003; Kim et al., 2011). 
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Another component of UPS is represented by the 26S proteasome: a 2000 kDa multi-subunit 
cylindrical complex constituted by one 20S catalytic core (20S proteasome) capped on both 
the sides by 19S regulatory components (Adams, 2003). In details, in the 20S proteasomal 
core, 4 stacked rings exist: two outer ɑ-rings and two internal β-rings. The last ones are 
composed by 7 subunits, responsible of the proteolysis thanks to three different enzymatic 
activities: trypsin-like, chymotrypsin-like and postglutamyl peptide hydrolase-like (or 
caspase-like) activities (Almond and Cohen, 2002; Adams, 2003). 
In summary, the complete process is ensured by the initial ubiquitylation, and then the Ub-
tagged proteins are recognized and bound by the 26S proteasome. However, for the 
transferring in the 20S core proteolytic chamber, the Ub signal should be previously removed 
from the target protein. This essential step is guaranteed and highly controlled by 
deubiquitinating enzymes (DUBs) (Komander et al., 2009) (Fig.2).  
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Fig.2: UPS: ubiquitylation process coupled with the 26S proteasome activity. The 
ubiquitylation process is an essential step to add the Ub-tag to the protein targets, recognized 
then by the 26S proteasome. The same tag is removed by DUBs activity for the protein 
transferring in the 20S proteasomal core, which is characterized by different proteolytic 
activities (biomol.com).
Introduction
1.1.2 Deubiquitinating enzymes (DUBs): activity and specificity 
The deubiquitination process is guaranteed by the enzymatic activity of the peptidases, named 
DUBs (Komander et al., 2009), which can catalyze: 
- the Ub/UbLs monomers and chains removal from the tagged protein, 
- the cleavage of the poly-ubiquitinylated chains, 
- the generation of free Ub monomers ready to be recycled. 
The DUBs control these reactions by hydrolyzing selectively the isopeptide or peptide bond 
present at the C-terminus of the Ub molecule (Komander, 2009).  
Many aspects regarding the capability of the DUBs to select and to recognize, in a specific 
way, the modifier or the branching patterns of the poly-Ub chains remain to be clarified. 
Nevertheless, it is well know that the DUBs, to deubiquitinate the substrate, need their UBD, 
which is characterized by an Ub-interacting motif, a zinc finger Ub-specific protease (ZnF-
UBP) domain and a Ub-associated (UBA) domain (Hurley et al., 2006). Some studies indicate 
that the specificity of the binding seems to be more attributable to the ZnF-UBP domain, 
ensuring a strictly regulation of the deubiquitination process (Komander, 2009).   
The high number of DUBs reflects the complexity of UPS (Reyes-Turcu et al., 2009). They 
have been divided in six structurally distinct DUB families. In particular, five are cysteine 
proteases: ubiquitin-specific proteases (USPs, 54 members in human), ovarian tumor 
proteases (OTUs, 16 members), Ub C-terminal hydrolases (UCHs, 4 members), Josephin 
family (4 members) (Clague et al., 2013; Komander et al., 2009) and the motif interacting 
with Ub (MIU)-containing novel DUB family (MINDYs, 4 members) (Rehman et al., 2016). 
An other family exist: the Zn-dependent JAB1/MPN/MOV34 metalloproteases (JAMMs, 16 
members). Regarding the UbL proteases, the sentrin/SUMO-specific proteases (SENPs), the 
deSUMOylating isopeptidases (DeSI) and the NEDD8-specific protease 1 (NEDP1, a SENP 
member) exist and they are all classified as ubiquitin-like proteases (ULPs) (Hickey et al., 
2012; Shin et al., 2012).  
Some DUBs are able to work individually, others as components of macromolecular 
machines. In particular, three DUBs are able to interact with the 26S proteasome: UCH37 
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(also known as UCH-L5), USP14 (Ubp6 in yeast), and the JAMM family DUB RPN11. These 
enzymes are involved in the engagement step of the Ub-tagged proteins on the cap of the 
proteasome with the help of the AAA+ ATPase ring (Fig.3).  
In this context, UCH37 is recruited to the proteasome by RPN13 (also known as ADRM1), 
through the binding between the RPN13 C-terminal domain (RPN13CTD) and the C-terminal 
domain of UCH37 (UCH37CTD). The latter one is an autoinhibitory domain (Yao et al., 
2006, 2008), which controls the N-terminal catalytic domain of UCH37 (UCH37UCH) 
(Burgie et al., 2012; Maiti et al., 2011; Nishio et al., 2009).  
RPN11 is located directly on the entry channel of the 20S proteasome core and its activation 
occurs when the enzyme is incorporated in the proteasome by an energy-consuming process. 
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Fig.3: The DUBs-mediated deubiquitination process. Different DUBs are involved in the 
Ub and polyUb chains cleavage from the target proteins, and in the Ub-chains disassembling 
to maintain the mono-Ub pool. Some of them (USP14 and UCHL5) are also associated with 
the 26S proteasome to ensure the Ub removal from the tagged proteins before their entry in 
this proteolytic channel (Gadhave et al., 2016). 
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Once activated, RPN11 binds the proximal Ub of the target protein and removes the entire Ub 
chain (Verma et al., 2002; Yao and Cohen, 2002). 
Similarly, USP14 is catalytically inactive, but when it binds the proteasome, an 800-fold 
activation occurs (Lee et al., 2010). This DUB plays a role in processing of incorrectly poly-
ubiquitinated proteins loaded onto the proteasome (Lee et al., 2016).  
The activity of these enzymes coupled with the UPS determine a timely-regulated degradation 
of the substrates and, a strong dysregulation of this system, can affect negatively the final fate 
of the cell. More specifically, the alteration of the DUB enzymatic activities has a strong 
implication in the onset and progression of multiple diseases, such as neurodegenerative 
diseases and cancer. Interestingly, in the cancer context, it has been well demonstrated that 
these proliferating cells are more sensitive to the proteasome blockage, in comparison to the 
normal cells. Since the tumor cells are characterized by a higher rate of protein synthesis, if 
the UPS is blocked, a large concentration of aberrant proteins are produced and cell death is 
triggered (Adams, 2004; Voorhees et al., 2003; Kisselev and Goldberg, 2001). This aspect has 
elicited an increased interest in the developing UPS inhibitors able to active death programs in 
cancer cells (Nalepa et al., 2006).  
1.2 UPS inhibition as cancer therapeutic strategy 
1.2.1 Targeting the proteasome in cancer cells 
UPS inhibitors (UPSI) are small molecules able to target and inhibit specific activities of the 
UPS components, leading to the accumulation of poly-ubiquitinated proteins, activation of 
multiple stress signals and appearance of cell death. They belong to a heterogeneous class of 
compounds that can be subdivided into 5 different categories: the peptide aldehydes, peptide 
boronates, the peptide vinil sulfones, the lactacystins and the peptide epoxyketones (Kisselev 
and Goldberg, 2001; Adams et al., 1999).  
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Among them, the dipeptide boronic acid bortezomib (Velcade/PS-341) is of particular interest, 
since it has been the first UPSI approved for the human application by United States Food and 
Drug Administration (FDA) and the European Medicine Evaluation Agency (EMEA). 
It is a reversible inhibitor of the chymotrypsin-like activity of the 20S proteasome β5-subunit 
(PSMB5), and of β1-subunit (with lower affinity) (Adams, 2004; Orlowski et al., 2002; 
Richardson et al., 2003 and 2005).  
Specifically, bortezomib was approved for the treatment of relapsed or refractory multiple 
myeloma in 2008 (Richardson et al., 2003; Kyle and Raijkumar, 2004). However, it is also 
studied in different haematological malignancies and solid tumors, including non-Hodgkin’s 
lymphoma, prostate, breast and non-small-cell lung cancers, as single agent or in combinatory 
therapies (Milano et al., 2007). Although this drug has shown promising effects, severe side 
effects were reported (thrombocytopenia, fatigue, myalgia, neuropathies), and some clinical 
limiting factors were found (oral administration, off-targets and acquired resistance). In fact, 
there is evidence about patients who do not respond, or respond briefly to the treatment, and 
then they relapse (Richardson et al., 2005; Milano et al., 2007). This aspect could be 
explained by some in vitro studies, which reveled the presence of Gly322Ala point mutation 
in the PSMB5 gene in the cells resistant to the treatment (Lü et al., 2008). Others mutations 
have been found around the S1 specificity pocket of the PSMB5, such as the Thr21Ala, 
Ala49Thr, Ala50Val substitutions, which could be directly involved in the bortezomib-
PSMB5 binding. All these acquired mutations negatively influence the binding between 
bortezomib and its target (Groll et al., 2006; Unno et al., 2002). Surprisingly, no mutations in 
PSMB5 gene have been detected in patients with refractory and relapsed multiple myeloma 
(Lü et al., 2011). Other studies demonstrated that the up-regulation of PSMB5 gene or the 
over-expression of the proteasome subunits, which lead to an augmented basal level of the 
proteasome activity, can explain the nature of the acquired or intrinsic drug resistance 
phenomena (Lü et al., 2008; de Wilt et al., 2012). Additionally, a significant adverse event, 
linked with the clinical use of bortezomib, is represented by the peripheral neuropathy. Some 
studied reported that this clinical issue is due to the inhibition of the neuronal survival protein 
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called HtrA2/Omi (Arastu-Kapur et al., 2011; Voortman and Giaccone, 2007). For all these 
reasons, it is urgent to find alternative compounds able to induce the cell death, by targeting 
the UPS, similarly to bortezomib, but limiting the risk factors.  
Among them, it is possible to find: 
- the second-generation UPSI, developed to improve the drug efficacy and to reduce the 
toxicity by targeting the ɑ-subunits or multiple β-subunits of the 20S proteasome in an 
irreversible way;  
- the DUBs inhibitors (Buac et al., 2013).  
Concerning the first class, Carfilzomib represents the second UPSI approved, as third line 
treatment in multiple myeloma, in 2012 and by EMA in 2015 (Kortuem and Stewart, 2013). 
This drug is characterized by several improvements: the capability to bind irreversibly the β5-
subunit (showing a greater selectivity and lower off-target binding activity), the covalent bind 
(ensuring a prolonged inhibition) and, more prominent, the cytotoxic effects on the 
bortezomib-resistant cells (Ruschak et al., 2011; Kuhn et al., 2007).   
Worthy of note are also ixazomib, since it is the first oral UPSI approved for the myeloma 
treatment in 2016 (Gupta et al., 2017), and oprozomib, which shows an augmented cytotoxic 
activity in cancer cells resistant to the other UPSIs (Nooka et al., 2013; Thompson, 2013).  
Considering their promising effects in the hematological malignancies, the possibility to use 
these UPSIs in the treatment of the most common solid malignancies has been explored. 
Recent studies suggest that they could be used, especially, in combination therapies with the 
classic anticancer drugs (Table 1).  
1.2.2 UPSI treatment: cellular effects and cell death activation  
The proteasome blockage triggers a multiple, profound and complex number of effects, which 
they contribute to the onset of cell death. Among them, the endoplasmic reticulum stress (ER 
stress) is involved (Fribley et al., 2004). 
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ER stress is activated upon the accumulation of poly-ubiquitinated proteins and misfolded 
protein aggregates into the cytosol of the UPSI-treated cells (Ri, 2016; Obeng et al., 2006). In 
parallel, the production of reactive oxygen species (ROS) is facilitated by the high amount of 
the cytosolic unfolded proteins (Shimizu and Hendershot, 2009). In this context, the 
activation of the unfolded protein response (UPR) is mediated by three ER stress sensors: 
PKR-like ER kinase (PERK), inositol requiring kinase1 (IRE1ɑ), and activating transcription 
factor (ATF6) (Kaufman, 2002; Harding et al., 2002). The UPR plays a pro-survival role, 
since it stimulates the protein translation blockage, the increase of ER-resident chaperon 
activities, and the activation of ER-associated degradation pathway (ERAD). All these 
processes are aimed to resolve the proteotoxic stress, by avoiding a further unfolded protein 
accumulation and by recovering the physiological folded statement of the cytosolic proteins 
(Ri, 2016). Analysis of the transcriptional profiling, by DNA microarray, of cancer cells 
exposed to UPSI reported the up-regulation of heat shock genes, genes encoding for the 
proteasome subunits and genes implicated in the protein folding regulation (Zimmermann et 
al., 2000). Nevertheless, if the ER stress is strong or prolonged, cell death occurs (Kaufman, 
2002; Ron, 2002). In this context, in which the proteasome is blocked, some critical pro-
apoptotic proteins, normally tagged to be degraded, are free to act, as in the case of: 
- IkBɑ, the natural inhibitor of the NF-kB, indispensable for the apoptosis inhibition and pro-
survival pathway activation (Lopes et al., 1997); 
 16
Table 1: Summary of the main UPSI clinical trials in different type of solid malignancies 
(clinicaltrials.gov). 
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-  p53, a very short-lived protein, whose stabilization and accumulation can strengthen the 
UPSI pro-apoptotic effects (Rastogi et al., 2015); 
-  Bim, which when stabilized, favors the accumulation of Bcl-2 family pro-apoptotic 
proteins (Brancolini, 2008; Demarchi and Brancolini, 2005).   
Nevertheless, in the absence of p53 functions and NF-kB inhibition, the UPSI-induced cell 
death can still be observed (Richardson et al., 2005; Demarchi and Brancolini, 2005).  
Caspases are a family of cystein-proteases able to cleave selected substrates after aspartic 
residues (Demarchi and Brancolini, 2005). They are responsible for the execution of the 
apoptotic program through two main ways: the extrinsic and intrinsic pathways (Fig.4). The 
extrinsic pathway is activated by the engagement of a death receptor (DR) family member on 
the cell surface. Caspase-8 (a component of the Death Inducing Signaling Complex (DISC)) 
is recruited at cytosolic side of DR via the interaction with the adaptor Fas-Associated Death 
Domain (FADD) protein. At the DISC, also the Fas-like inhibitor protein (FLIP) is recruited. 
All these proteins modulate the caspase-8 recruitment and its subsequent activation within the 
cell, in response to pro-apoptotic stimuli (Thorburn, 2004; Oliver and Vallette, 2005). The 
intrinsic pathway is elicited by the efflux of some mitochondrial pro-apoptotic proteins into 
the cytosol, such as cytochrome c (cyt c), second mitochondria-derived activator of caspase/
Direct Inhibitor of Apoptosis-Binding protein with LOw pI (Smac/DIABLO) and OMI/
HtrA2. For this reason, the intrinsic pathway is also named mitochondrial pathway. Upon the 
cytosolic release of these killer proteins, the caspase-9 is activated through the formation of a 
multi-protein complex known as the apoptosome, driven by the binding of cyt c to Apaf-1 
(apoptotic protease activating factor-1). Consequently, the effector caspases-3 and -7 are 
processed (Jiang and Wang, 2004). Caspases-8 and -9 are the regulatory factors that control 
the effector caspases, which in turn act on selected cellular substrates to provoke the final 
cellular disassembly.  
In the UPSI-induced cell death, even if there are several controversial points, the 
mitochondrial outer-membrane permeabilization (MOMP) triggers the release of cyt c and 
Smac, which in turn elicit the processing and activation of caspases-9, -3 and -7. In this 
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scenario, high levels of cytosolic Smac, allowed by proteasomal blockage, favors an 
apoptosome-independent apoptotic response (Henderson et al., 2005). Moreover, Inhibitor of 
Apoptosis Proteins (IAPs), such as XIAP, cIAP1 and cIAP2, are under the proteasome control 
and, in principle, their increase should prevent the caspases activation (Vaux and Silke, 2005). 
However, it is reported that bortezomib determines the down-regulation of XIAP in vivo 
(Fernandez et al., 2005; Frankel et al., 2000; Dai et al., 2003), which could be explained by 
the ability of NF-kB to control some IAPs. Hence, in an indirect way, the NF-kB inhibition 
could promote the XIAP down-regulation, but a NF-kB independent XIAP down-regulation 
was reported in response to bortezomib (Kashkar et al., 2007). This event is more complex 
than expected, since also IAP antagonists exist: they share a sequence at the N-terminus called 
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Fig.4: Apoptosis. Schematic representation of the apoptotic mechanisms activated by two 
ways: the intrinsic and extrinsic pathway (de Vries et al., 2006). 
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IBM (IAP Binding Motif) (Vaux and Silke, 2005), and they can sustain apoptosis by 
counteracting the IAPs activities (Vaux and Silke, 2005; Schimmer, 2004; Shiozaki and Shi, 
2004).        
Regarding the extrinsic pathway, it was demonstrated that the UPSI treatment can elicit 
apoptosis through the DR pathway (Van Geelen and de Vries, 2004; Saule et al., 2007). In 
fact, in cancer cells, the treatment with these inhibitors leads to the up-regulation of severe 
DR members and their respective ligands: DR4/TRAIL-R1 (TNF-related apoptosis-inducing 
ligand (TRAIL)-receptor1), DR5/TRAIL-R2 and DcR2/TRAIL-R4. They are not only 
accumulated, but also activated in a still unclear way (Liu et al., 2007; Ganten et al., 2005; 
Aleo et al., 2006; Kabore et al., 2006). 
Additional studies are necessary to gain new insights about the UPSI-induced cell death 
pathways. Until now, it is clear that an unmanageable stress is induced in the UPSI-treated 
cancer cells, which finally die. The antineoplastic activity of these inhibitors seems to be 
linked to triggering apoptosis, but new findings are coming out regarding their ability to elicit 
additional cell death pathways (D’Arcy et al., 2011; Fontanini et al., 2009).        
1.2.3 DUBs inhibitors: an emergent class of UPSI 
In general, a heterogenous group of small molecule, able to inhibit the DUBs, has been 
reported: some are broad pan-enzyme inhibitors, others show a more specific inhibitory action 
(Fig.5).  
For example, b-AP15 was identified as an inhibitor of the deubiquitinating activities of 
USP14 and UCHL5, without affecting directly the 20S proteasome (Tian et al., 2014; Wang et 
al., 2015). Like all UPSIs, the b-AP15 triggers the unfolded protein response (UPR) through 
the accumulation of poly-ubiquitinated proteins, growth arrest (due to the down-regulation of 
CDC25C, CDC2 and cyclin B1) and the induction of caspase-dependent apoptosis. In vivo 
xenograft studies reported the promising effects of b-AP15 treatment on human multiple 
myeloma (Tian et al., 2014), and on solid tumor mouse models of lung, colon, breast, head 
and neck carcinomas (Dou and Zonder, 2014).  
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b-AP15 shares the pharmacophore with a class of non-selective inhibitors (N-SIIs) previously 
identified (Aleo et al., 2006; Mullally and Fitzpatrick, 2002). The pharmacophore is 
characterized by a cross-conjugated ɑ,β-unsaturated dienone with two sterically accessible 
electrophilic β-carbons (Verbitski et al., 2004). The β-carbons act as Michael acceptors to 
target nucleophiles, such as the free sulfhydryl groups of catalytic cysteines in the 
isopeptidases. Indeed, the cysteine is the most nucleophilic and reactive amino acid within a 
cell (Mullally and Fitzpatrick, 2002). 
In vitro studies with recombinant proteins demonstrated the heterogeneity of N-SIIs targets, 
such as the UCHs, USP2, USP7 and the UbL-protease SENP2 (Nicholson et al., 2008). 
 20
Fig.5: Summary of DUB inhibitors and their targets. Some of them are specific for 
selected DUB enzyme, others show broader activities (Mattern et al., 2012). 
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Additionally, N-SIIs can react with other thiol-containing compounds. such as the glutathione 
(GSH) (Foti et al., 2009). 
On the contrary to selective inhibitors, the N-SIIs arise interest since, by blocking different 
enzymes in multiple signaling pathways, they can be more effective in term of toxicity in a 
wider range of tumors, overcoming in this way the possible onset of drug-resistance. Another 
relevant advantage, regarding the possible use of N-SIIs as therapeutic agents, is the 
possibility to modify their chemical structure, thus promoting the triggering of a different type 
of cell death. In fact, in the anticancer-therapy context, the acquisition of some defects in the 
execution of the apoptotic program is a problem to be considered. The apoptotic resistance 
represents one of the major causes of chemotherapy failure. Consequently, a goal to achieve, 
for the new anti-cancer therapies, is the discovery of compounds able to elicit cell death 
programs different from apoptosis (Rodriguez-Nieto and Zhivotovsky, 2006). All these 
reasons led us to focus our attention on a N-SII called G5, especially for its ability to trigger a 
peculiar necrotic pathway of cell death (Tomasella et al., 2014; Foti et al., 2009). 
1.2.4 The promising N-SII G5: its discovery and derivates 
The G5, a 4H-thiopyran-4-one, tetrahydro-3,5-bis[(4-nitrophenyl)methylene]-,1,1-dioxide 
(Fig.6), was identified thanks to a screening with a small chemical library (the Developmental 
Therapeutics Program-National Cancer Institute “challenge set”) carried out on cells 
expressing a dominant-negative form of caspase-9 (C9DN), unable to assemble a functional 
apoptosome (Aleo et al., 2006). The aim was to identify new drugs able to elicit alternative 
cell death pathways in apoptosome-defective cells.  
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Fig.6: Structure of the N-SII G5 (Cersosimo et al., 2015). 
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Despite the G5-induced cell death mechanism was not perfectly clear, numerous efforts have 
been made to optimize this N-SII for in vivo use. Indeed, the N-SII G5 compound was 
modified by varying separately different atoms in different positions (Cersosimo et al., 2015). 
By testing these variants on glioblastoma U87MG cells, it was observed a different capability 
to elicit an apoptotic or necrotic response, in base on the chemical substituents of the tested 
variants. Among all, the compound called 2c raised interest especially for the presence of a 
reactive -OH group. This group could be easily modified to improve some drug-like 
properties, such as the in vivo delivery (Cersosimo et al., 2015). Functional studies on G5 and 
2c inhibitory activities revealed a stronger potential of G5 to inhibit DUBs such as UCHL1, 
UCHL5 and USP2, but less the deISGylase USP18, which was, on the contrary, more 
inhibited by 2c. This aspect could explain the differential ability of these inhibitors to trigger 
necrosis or apoptosis, by reacting with different cysteine proteases (Cersosimo et al., 2015). A 
further understanding of the intracellular targets bound by this class of inhibitors could shed 
light on the way through which cell death is engaged. 
G5 and 2c are insoluble in aqueous solutions, so the in vivo delivery should be improved for 
their application in the anti-neoplastic therapy. For this reason, the 2c compound was 
conjugated with polyethylene glycol (PEG) to increase its solubility and bioavailability. This 
modified version, called 2cPE, represents the first synthesized N-SII pro-drug. Specifically, 
the phospholipase A2 group 7 (PLA2G7) seems to be the responsible of conversation from the 
pro-drug 2cPE into the active form 2c (Cersosimo et al., 2015). This pro-drug was tested on 
A549 lung carcinoma xenografts generated in immunocompromised mice by intravenous 
injections, and it showed a strong anti-neoplastic activity in vivo, as single agent, without 
significant adverse effects (Fig.7). Moreover, the in vivo effects of 2cPE are particularly 
marked in tumor cells than in liver or others organs, highlighting the real possibility to use it 
in clinic.  
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1.2.5 G5: a peculiar necrotic cell death trigger 
G5 elicited considerable interest for its ability to trigger a Bcl-2-dependent but apoptosome-
independent pathway of cell death (Aleo et al., 2006). G5-treated cells showed a complex 
response, since different biological processes are affected, and several pro- and anti-apoptotic 
factors are accumulated. As described for the UPSI, the G5-treatment leads to the expression 
and activation of the DR pathway, the cytosolic localization of Smac, the engagement of p53 
and the inhibition of NF-kB (Richardson et al., 2005; Aleo et al., 2006). Even if the 
involvement of these two master administrators of survival/death (p53/NF-kB) was reported, 
the G5-dependent cell death can take place independently from them (Richardson et al., 2005; 
Demarchi and Brancolini, 2005). 
As for the UPSI-elicited cell death, the DR pathway, concomitantly with the reduction of anti-
apoptotic c-FLIP levels, can facilitate the cell death induction (Sayers et al., 2003). In this 
context, also the contribution of Smac should be considered as enforcer of the cell death, 
especially because it was demonstrated that its cytosolic accumulation can override the 
protection given by the anti-apoptotic Bcl-2 protein, which can free the effector caspases from 
IAP inhibition also in absence of the apoptosome formation (Sun et al., 2002; Aleo et al., 
2006). 
 23
Fig.7: Modified version of the N-SII G5, 2cPEG, and its in vivo study.  Starting from 2c structure, 
the OH group has been PEGylated to improve the in vivo delivery of the drug. On the right, the 
development in terms of tumor volume of A549 lung carcinoma xenografts generated in mice upon 
the subcutaneous (sc) or intravenous (iv) treatments with 2cPE (Cersosimo et al., 2015). 
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Although the apoptosis is surely involved, recently the contribution of alternative pathways 
was reported. Indeed, one of the most fascinating aspect of G5 regards its capability to trigger 
a peculiar necrotic response in cancer cells resistant to apoptosis (Fontanini et al., 2009). A 
deeper investigation of the G5-elicited molecular pathway was performed on glioblastoma 
cells, since glioblastomas (GBM) are one of the most lethal tumors characterized by high 
resistance to radiotherapies and chemotherapies. The resistance to apoptosis and the 
susceptibility to die by necrosis lead, this type of tumor, to be an ideal model for the 
characterization of G5 necrotic activity (Furnari et al., 2007).  
Study performed on the two GBMs cell lines U87MG and T98G shed some lights on the cell 
mechanisms triggered by G5 (Foti et al., 2009). U87MG cell line showed an increased 
susceptibility to die by necrosis upon G5 treatment, in comparison to T98G cells. The 
expression profile analysis and functional studies, on these two cell lines, unveiled that the 
differential responsiveness to G5 could be due to the different expression of GSH-
detoxification system and to the differential ability to adhere with the extracellular matrix 
(ECM) (Foti et al., 2009). In fact, the G5-induced necrosis was partially influenced by the 
ECM adhesion, but not by PARP activation or Bcl-2 or Bcl-xL inhibition, as shown in the 
study on murine embryonic fibroblasts derived from mice double-deficient for Bax and Bak 
(double knock-out; DKO) (Fontanini et al., 2009). PARP (poly(ADP-ribose) polymerases) is a 
well-known enzyme involved in the DNA damage repair response, and it has a role in the 
induction of necrosis in presence of DNA-alkylating compounds (Zong et al., 2004). In the 
PARP-induced pathway, the receptor-interacting protein 1 (RIP1) and c-Jun N-terminal kinase 
(JNK) are activated by various environmental stresses leading the cell to die by necrosis (Xu 
et al., 2006). By inhibiting separately these elements of the necrotic response, the G5-induced 
cell death was not affected (Fontanini et al., 2009), emphasizing the possibility of a new 
peculiar mechanism of cell death.  
Starting to understand the capability of G5 to induce necrosis, an another study was 




Necroptosis was described as regulated cell death program activated by tumor necrosis factor 
ɑ (TNF-ɑ), TLR (toll-like receptors), interferon, and also by viral and bacterial agents or 
multiple pathophysiological signals (Berghe et al., 2014). The morphological features were 
described, for the first time, by Vercammen and colleagues on L929 cells upon the caspases 
blockage by the inhibitor z-Val-Ala-Asp.fluoromethylketone (zVAD-fmk) (Vercammen et al., 
1998). They also observed that this pathway stimulates an inflammatory response since the 
treated cells, after the increase of cell volume and plasma membrane rupture, collapse and 
release the cellular content in the surrounding environment. 
Several studies in the following years identified the nature of the execution complex involved 
in this type of cell death: the necrosome, which is the responsible of the final cellular demise. 
This multi-protein complex includes the receptor interacting protein kinase 1 (RIPK1), RIPK3 
and mixed kinase domain-like (MLKL) (Berghe et al., 2014; Newton et al., 2016). Upon its 
activation, MLKL translocates on the plasma membrane to bind phosphoinositolphosphate 
(PIPs) molecules, and it forms some pore-forming structures, through which ions (as sodium) 
diffuse (Chen et al., 2014). The intracellular osmotic pressure is increased and the membrane 
collapse appears (Dondelinger et al., 2014). The MLKL behavior recalls the Bax and Bak 
proteins function on the outer mitochondrial membrane.  
Another recent study described the capability of RIPK3-MLKL complex to translocate on 
mitochondria membranes to initiate the intrinsic pathway of necroptosis (Chen et al., 2014). 
This event together with the participation of the mitochondrial phosphatase PGAM5, which in 
turn activates the dynamin-related protein 1 (Drp1), seems to be essential for the 
mitochondrial fragmentation and for the final execution of the necroptotic pathway (Wang et 
al., 2012). The PGAM5 and Drp1 involvement is still unclear and debated, since several 
studies excluded their requirement in this type of cell death (Moujalled et al., 2014; Tait et al., 
2013). Nevertheless, it is emerging an even more close connection between this regulated 
mechanism of necrosis and the intrinsic pathway of apoptosis, since they can proceed 
simultaneously, rendering more complex to define in which way a cell can die (Belizário et 
al., 2015; Fig.8).   
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To better understand on which components of the cell death G5 relies, a comparative study 
was performed between this N-SII and DMNQ. The DMNQ (2,3-Dimethoxy-1,4-
naphthoquinone) acts as redox-cycling agent, and it is normally used as a tool to generate 
reactive oxygen species (ROS), especially the superoxide and hydrogen peroxide species 
(Kaas et al., 1989). In fact, this drug is able to cross the plasma membrane and, in the 
intracellular environment, it is reduced by flavoenzymes (such as NADPH-cytochrome P450 
reductase) producing semiquinone radicals. These species can react with the oxygen, forming 
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Fig.8: Cell death mechanisms. Comparison between the molecular mechanisms of 
apoptosis: the extrinsic pathway in A and the intrinsic pathway in B.  The necroptosis 
(here called regulated necrosis) is shown in C. The differential complexes involved in 
the execution of the cell death pathways are reported (Galluzzi et al., 2012). 
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superoxide and, in turn, hydrogen peroxide. Not only, reactive and unstable hydroxyl radicals 
can be produced in presence of Fenton metals, determining the onset of the oxidative stress 
within the cell (Shi et al., 1994; Gant et al., 1988). The generated oxidative stress alters 
multiple cellular parameters, including the mitochondrial membrane potential (Klotz et al., 
2014).  
Comparing the responses of U87MG cells to these two drugs, different aspects were observed. 
The DMNQ-induced cell death requires the necroptotic components RIP1 and Drp1 and 
mitochondrial fragmentation, whereas the G5-triggered pathway occurs independently from 
them (Tomasella et al., 2014). In the G5-elicited mechanism, others components were pointed 
out: the phosphatase PP2A and its substrate Cofilin-1. Specifically, the catalytic subunit, of 
the Ser/Thr phosphatase PP2A, is stabilized upon the G5 treatment, and also an increase of its 
enzymatic activity was reported. Although in the cell death induced by the two stressors, an 
opposite role for PP2A was described, this phosphatase translocates from the nucleus into the 
cytoplasm, concomitantly with the well-known necrotic marker HMGB1. This aspect leaves 
open the possibility that the PP2A enzyme can organize a specific cytosolic necrotic complex 
able to drive the cell death (Tomasella et al., 2014).  
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Fig.9: Comparison of DMNQ- and G5-induced cell death pathways. Different 
intracellular effects and activated pathways are involved in response to the two 
necrotic stressors: the ROS generator DMNQ and the N-SII G5 (Tomasella et al., 
2014). 
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Since cytoskeletal alterations are evident in the G5-treated cells, it was thought to study 
Cofilin-1, the PP2A substrate, which is characterized by an actin depolymerizing activity. G5 
treatment induces the activation of Cofilin-1, by dephosphorylating its Ser3, in a PP2A-
dependent manner. Nevertheless, the expression of a Cofilin-1 phosphomimic mutant in the 
U87MG cells, and their following treatment with G5, reveal a partial involvement of this 
actin-binding protein, emphasizing that others elements are required for the execution of G5-
elicited pathway (Tomasella et al., 2014; Fig.9).  
Obviously, a complete and clear description of the peculiar necrotic program elicited by G5 is 
necessary. In fact, the promising effect of G5 is given by its capability to trigger a different 




2. Aim of the study  
Acquisition of mutations/alterations in the apoptotic machinery is one of the main cause of the 
chemotherapy failure in cancer cells. For this reason, it is interesting to find new compounds 
able to elicit alternative cell death pathways. Among them, the non-selective DUB inhibitor 
G5 represents a promising therapeutic agent for its ability to induce a proteotoxic stress-
dependent necrotic pathway. This pathway is largely unexplored. Previous studies have 
demonstrated the role played by the PP2A/Cofilin-1 axis, but other key proteins and signaling 
events are possible involved. To better dissect the G5-elicited death mechanisms, two 
strategies have been followed: i) a proteomic approach to map additional cellular targets of 
this compound, and ii) an unbiased screening using a shRNA library to identify critical genes 
in the G5-induced necrotic death. The general aim of this thesis was to reveal new death 
signaling pathways, operating in glioblastoma cells, by using different genome and genetic 
editing approaches, such as the RNA interference and the CRISPR-Cas9 system. 
In parallel, the effects of the G5-derivate 2cPE, optimized for in vivo delivery, has been 
studied in a different cancer context: the B-cell chronic lymphocytic leukemia (B-CLL) in 
comparison to bortezomib, the first UPS inhibitor approved in clinic. Since these results have 
been already published they are included as appendix of this thesis. Hence, the result section 




3.1 High-throughput shRNA library screening to identify genes involved in 
transducing G5-induced cell death   
To uncover key genes controlling the G5-induced necrosis, we conducted an unbiased pooled 
short hairpin RNA (shRNA) screening on U87MG cells, a cellular model chosen for its 
natural propensity to die by necrosis (Foti et al., 2009). The used DECIPHERTM human 
module 1 of the library contains 27500 shRNAs targeting 5046 signaling components.  
The basis of this type of technology is the stable suppression of thousands of different targets 
on a large scale, allowing us to obtain a simultaneous loss-of-function screening in a single 
experiment. In this way, it is possible to identify genes functionally involved in triggering the 
G5-induced pathway, since they ablation should promote a growth advantage. 
U87MG cells were infected with the lentiviral library encoding the highly heterogeneous 
population of barcoded shRNA constructs for two days. The infection was performed into a 
population of 33 millions of cells, to exceed the complexity of the library for at least 200 
times. A very low multiplicity of infection (MOI of 0,1) was selected, in order to have the 
expression of a single shRNA in single cells. Two days later, the infected cells were selected 
with puromycin and after three days, the surviving population of cells, harboring different 
shRNAs, was treated with G5 for 60 hours. G5-treatment should permit the exclusive survival 
of those cells, which contain and express shRNAs able to silence genes required for G5 death-
related activities (Fig.10A). To discover the identity of these genes, the genomic DNA was 
extracted from the surviving cells and the abundance of every integrated shRNA-specific 
barcode was amplified by PCR with vector-specific primers and identified using high-
throughput (HT) sequencing. The barcodes are unique and specific sequences of 18-
nucleotides permanently associated with the shRNA expression cassette. These sequences 
enable an unambiguous identification of each shRNA upon the HT sequencing. The 
deconvolution and normalization of the reads for each barcode respect to “neutral” shRNAs, 
present in the library, reveled the identity of the most enriched shRNAs. Moreover, since in 
the library, for every target were present from 5 to 6 different shRNAs, relevant “hits” were 
defined those genes with at least two different shRNAs enriched in comparison to the 
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shRNAs against the luciferase (NshRNAs ≥ 2), the control gene (Fig.10B). As it is shown in the 
graph, among the top target genes were identified: RNASEL, POU5F1, GSK3β, CAPN1 and 
DUSP10. We focused our attention on glycogen synthase kinase-3 β (GSK3β), since it is well 
known to be a stress-induced kinase (Cheng et al., 2016; Song et al., 2002), and because it is 
involved in different cell death pathways under specific cellular contexts (Beurel and Jope, 
2006; Sun et al., 2008; Gómez-Sintes and Lucas, 2010). Finally and most important, among 
other hits, well-known interacting proteins/regulators of GSK3β were detected, such as 
Calpain 1 (CAPN-1) (Goñi-Oliver et al., 2007), and the protein phosphatase-1 (PPP1) 
(Felgueiras and Fardilha, 2014) (Fig.10C).  
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Fig.10: Followed experimental approach and identification of hits by the 
DECIPHERTM pooled shRNA library. (A) Schematic representation of the screening 
protocol. 33 millions of U87MG cells were infected with the lentiviral particles containing 
the shRNA plasmids for two days. For the selection of the expressing-shRNAs, the cells 
were selected with puromycin (2 µg/ml) for three days. Later, the selected cells were treated 
with the necrotic tigger G5 (2,5 µM) for 60 hours and the surviving cells were harvested to 
recover the genomic DNA. (B) By PCR-amplification, HT sequencing, and normalization on 
Luciferase shRNAs, the most enriched hits were represented (NshRNAs ≥ 2). (C) Among the 
identified hits, the GSK3β and its specific interacting proteins, such as CAPN1 and PPP1, 
were detected.
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3.2 Validation of hits library through RNAi  
Since the involvement of CAPN1 in different cell death programs is well known, and, to 
validate our shRNA library screening, the silencing of CAPN1 was performed using a siRNA 
targeting a different region of the gene. In addition, a siRNA against PP2AC was used as 
positive control. In fact, it was previously demonstrated that PP2AC down-regulation 
decreased G5-induced cell death (Tomasella et al., 2014).  
U87MG cells with down-regulated CAPN1 and PP2AC proteins were less sensitive to the 
G5-treatment, in comparison with the control transfected cells. The potency of silencing was 
confirmed by the reduction of the respective protein levels, as shown in the immunoblot 
analysis (Fig.11A).  
To validate GSK3β as an element of G5-induced cell death pathway, a specific siRNA was 
transfected in both U87MG and U87MG-BCLXL cells. U87MG-BCLXL cells were used to 
confirm the role of GSK3β in the necrosis regulation and, not in the apoptosis, since BCLXL 
over-expression further suppresses the apoptotic cascade activation. Cells were subjected to 
72 hours of silencing. In both cell lines, when GSK3β was down-regulated and, cells were 
treated with G5, the reduction of the GSK3β mRNA expression was correlated with a slight 
decrease in cell death in comparison to cells transfected with a control siRNA (Fig.11B).  
In summary, the involvement of GSK3β in the necrotic pathway triggered by G5 is unclear, 
given that its silencing was not able to strongly affect the cell death appearance. To clarify if 
this partial effect was due to the modest RNAi-mediated down-regulation of the kinase under 
consideration, the CRISPR/Cas9 system was applied to obtain the full abolition of GSK3β 
protein in U87MG cells.  
3.3 Generation of GSK3β knock-out cells and their characterization 
To apply the CRISPR/Cas9 system and to generate knock-out (KO) cells for GSK3β, a single 
guide RNA (sgRNA) complementary to the exon 1 of GSK3β gene was designed and the wild 
type (wt) Cas9 was used. After the screening of 253 isolated clones, one putative U87MG/
GSK3β KO clone (number 19) was identified. The immunoblot analysis demonstrated the 
complete absence of the GSK3β protein in these cells, in comparison to two types of U87MG/
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GSK3β+/+ control cells (Fig. 12A). The GSK3β+/+ control cells were represented by a clone 
derived from U87MG cells infected exclusively with Cas9 wt, but not with the sgRNA 
(control sample), and by other clone (number 63), which was one of the screened clones that 
resulted wild-type for GSK3β (WT sample).  
The genomic DNA (gDNA) of the putative GSK3β-/- clone was extracted and sequenced in 
order to find the origin of the mutation that causes the absence of the kinase. The sequencing 
demonstrated that the GSK3β gene in the KO cells was characterized by the insertion of one 
thymidine in the exon 1, exactly two nucleotides later the PAM, in both the alleles. 
Consequently, in the corresponding amino acid sequence the introduction of a premature stop 
codon was observed as product of the frameshift dictated by the insertion. This event explains 
the total absence of the GSK3β protein in U87MG KO cells (Fig. 12B). 
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Fig.11: Validation of identified hits in U87MG G5-treated cells. (A) Cytofluorimetric 
analysis showing the percentage of cell death in U87MG cells silenced for 48 hours for 
CAPN1 or PP2AC, and G5-treated for 24 hours (10 µM). The cellular lysates from down-
regulated cells were tested by immunoblot. Antibodies anti-CAPN1, anti-PP2AC, and 
anti-actin (as loading control) were used. (B) Cytofluorimetric analysis showing the 
percentage of cell death in U87MG and U87MG-BCLXL cells silenced for 48 hours for 
GSK3β, and G5-treated for 24 hours (10 µM). GSK3β mRNA levels, in the down-
regulated U87MG cells, were reported in comparison to GSK3β mRNA expression in 
control transfected cells. Data were from 3 experiments. Columns mean loss of viability + 
SD. *=p<0.05; **=p<0.01; ***=p<0.01.
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The U87MG/GSK3β-/- cells represent the ideal model to study the role of this kinase in the 
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Figure 12: Generation of U87MG/GSK3β KO clone and its response to G5 treatment. (A) 
Immunoblot analysis of GSK3β protein expression on lysates obtained from U87MG control 
cells (infected with Cas9 wt, without the sgRNA), from the clone 63 (infected with Cas9 wt and 
the sgRNA, but resulted wt for GSK3β), and from GSK3β-/- cells (clone 19). Antibodies anti-
GSK3β and anti-actin (as loading control) were used. (B) Nucleotide sequence of GSK3β gene 
in the U87MG/GSK3β-/- cells aligned to the wt sequence. In the exon 1 of the GSK3β gene, two 
nucleotide after the PAM, an insertion of one thymidine (in red) was found in both the alleles 
(only one allele is reported). The corresponding amino acid sequence of the KO clone is shown. 
The frameshift due to the mutation is highlighted in blue and the introduction of a premature 
stop codon (in red) explains the absence of the kinase in the clone 19. (C) Cytofluorimetric 
analysis showing the percentage of cell death in GSK3β control, GSK3β WT and GSK3β KO 
cells treated with G5 for 24 hours (2,5-5-10 µM). Data were from 3 experiments. Columns 
mean loss of viability + SD. *=p<0.05; **=p<0.01; ***=p<0.01.
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cell death pathway elicited by G5. For this reason, these cells and the relative control cells 
were treated with an increasing concentration of the inhibitor for 24 hours. Surprisingly, the 
GSK3β KO cells showed a modest resistance to the G5-treatment exclusively with the higher 
concentration (10 µM), similarly to cells knocked-down by RNAi (Fig. 12C). The obtained 
results suggest a partial role for GSK3β in transducing the G5-induced cell death signals, 
leaving unsolved the question about the nature of other regulators possible involved in this 
peculiar cell death pathway. On the other hand, these data strengthened the role of GSK3β in 
the necrotic regulation, given that the G5-treatment is able to directly elicit a necrotic 
response in the cells treated with highest concentration of the drug (Fontanini et al., 2009). 
G5 triggers pleiotropic stresses, which can drive cells to death, such as: proteotoxic stress, 
oxidative stress and cytoskeletal malfunctions, thus, the partial impact of GSK3β knock-out 
could stem from a co-existence of multiple cell death pathways. 
To prove this hypothesis, we selected DMNQ, an inducer of oxidative stress. DMNQ-induced 
cell death involves the necroptotic component RIP1, Drp1, and mitochondrial fragmentation. 
G5, by contrast, acts mainly through different pathways, even if it affects the mitochondria. 
The DMNQ-treatment of U87MG/GSK3β-/- cells and relative control cells (control and WT) 
showed that GSK3β was strongly required to trigger cell death in response to DMNQ (Fig.
13A). The contribution of GSK3β to the DMNQ-induced cell death, it was validated by RNAi 
experiments. In fact, U87MG cells, down-regulated for GSK3β, were less sensitive to the 
oxidative stress-induced cell death pathway caused by DMNQ exposure. The decreased 
protein levels of GSK3β, in the corresponding silenced cells, was confirmed by immunoblot 
analysis (Fig.13B).  
In summary, GSK3β plays a minor role during G5-induced cell death, but a major role in the 
DMNQ-elicited cell death pathway. 
3.4 Phenotype rescue in the U87MG/GSK3β-/- cells re-expressing GSK3β 
To further confirm that GSK3β was effectively involved in the onset of cell death, in response 
to the oxidative stress generated by DMNQ, we re-expressed GSK3β in the U87MG/GSK3β-/- 
cells. Specifically, two variants of the GSK3β protein were re-expressed: GSK3β wild type 
(WT) and GSK3β kinase mutant (KM), both C-terminal GFP-tagged. The DNA sequencing 
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confirmed, in the GSK3β KM sequence, the presence of a mutation located in the amino acid 
85 (K85A) in the kinase domain (data not shown). This mutation determines the inability of 
the kinase to act on its substrates. Thus, in the U87MG/GSK3β-/- cells re-expressing GSK3β 
KM, the kinase can be activated, but it cannot phosphorylate the specific intracellular 
substrates.  
The re-expression of the two GSK3β variants was performed into the U87MG/GSK3β+/+ and 
GSK3β-/- cells. U87MG/GSK3β+/+ and GSK3β-/- cells expressing only the Neomycin 
resistance were used as control (Neo cells). In Fig.14A, the immunoblot analysis proved the 
successful re-expression of WT and KM versions in both the GSK3β+/+ and GSK3β-/- cells. 
Subsequently, the engineered cell lines were treated with DMNQ, in order to understand, if 
the  re-expression of the WT form of GSK3β, was able to re-establish the sensitivity to die. 
The reported results showed that only the U87MG/GSK3β-/- cells expressing GSK3β WT, but 
not the KM version, entered cell death after DMNQ treatment (Fig.14B). On the contrary, the 
DMNQ-treated U87MG/GSK3β-/- cells re-expressing the inactive form of GSK3β were not 
rescued in terms of cell death. The morphology of the different cell lines before and after 
DMNQ treatment is reported in Fig.14D. Here, it is possible to recognize the presence of dead 
cells, upon DMNQ treatment, in the case of U87MG/GSK3β-/- cells re-expressing GSK3β 
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Figure 13: Resistance phenotype correlated to the absence and down-regulation of 
GSK3β upon the DMNQ-treatment. (A) Cytofluorimetric analysis showing the percentage 
of cell death in U87MG/GSK3β control, GSK3β WT and GSK3β KO cells treated with 
DMNQ for 24 hours (20 and 30 µM). (B) Cytofluorimetric analysis showing the percentage of 
cell death in U87MG cells silenced for 48 hours for GSK3β, and treated with DMNQ for 
further 24 hours (30 µM). At 48 hours of silencing, cellular lysates, from the down-regulated 
control and GSK3β cells, were harvested and tested by immunoblot. Antibodies anti-GSK3β, 
and anti-actin (as loading control) were used. Data were from 3 experiments. Columns mean 




Figure 14: Phenotype rescue in response to DMNQ in the U87MG/GSK3β-/- cells re-expressing 
GSK3β wild type. (A) Immunoblot analysis of lysates obtained from U87MG/GSK3β+/+ and GSK3β-/- cells 
re-expressing GSK3β WT or KM version. The exogenous form of GSK3β in frame with GFP was reveled 
at 75 kDa (GSK3β-GFP) and the endogenous one at 45 kDa. Antibodies anti-GSK3β, and anti-actin (as 
loading control) were used. (B) Cytofluorimetric analysis showing the percentage of cell death in U87MG/
GSK3β+/+ and GSK3β-/- cells re-expressing GSK3β WT or KM, treated with DMNQ for 24 hours (30 µM). 
Data were from 3 experiments. Columns mean loss of viability + SD. ***=p<0.01. (C) Immunoblot 
analysis of lysates obtained from U87MG/GSK3β+/+, GSK3β-/- and GSK3β-/- cells re-expressing GSK3β 
WT, treated with DMNQ (30 µM, for the indicated times) or bortezomib (100nM) for 4 hours plus TRAIL 
(2,5 ngr/ml) for further 20 hours. Anti-Casp2, anti-HDAC4 and anti-actin antibodies were used. (D) The 
same cells in B were imaged with Leica DMi1 microscope with a 10x objective before and after the DMNQ 





WT, but not in the case of cells expressing the kinase death mutant KM or the Neo gene 
alone. Overall, these results further validate the crucial role of GSK3β in the DMNQ-induced 
oxidative stress death pathway and prove the dependence on the kinase activity. 
Finally, to confirm that death induced by DMNQ was necrotic/caspase-independent, two 
caspase substrates were tested: Caspase-2 and HDAC4. It is known that, during apoptosis, 
HDAC4 translocates into the nucleus upon its cleavage, and this event is mediated by the 
activated Caspase-3/-2 (Paroni et al., 2004).  
U87MG/GSK3β+/+ cells, treated with an apoptotic stimulus (bortezomib and TRAIL co-
treatment), were used to compare the two different cell death responses (Unterkircher et al., 
2011). Immunoblot analysis of DMNQ-treated U87MG/GSK3β+/+, GSK3β-/- and GSK3β-/- re-
expressing GSK3β-WT cells, in comparison to bortezomib/TRAIL-treated U87MG/GSK3β+/+ 
cells, showed that the cleaved forms of Caspase-2 (p33 and p18), and cleaved fragments of 
HDAC4, were detected only in the lysates obtained from cells treated with the combination of 
the two apoptotic stressors (Fig.14C). Moreover, the reduction in HDAC4 levels, observed at 
later time points from DMNQ treatment (only in the presence of GSK3β), could be related to 
the ability of the kinase to influence HDAC4 poly-ubiquitylation and degradation (Fig.14C).  
To conclude, the role played by GSK3β in necrosis, triggered by oxidative stress, was fully 
confirmed.      
3.5 DMNQ activates GSK3β and triggers mitochondrial dysfunction 
To explore whether GSK3β is activated in the pathways triggered by DMNQ and G5, the 
phosphorylation status of Ser9 GSK3β was evaluated. This amino acid residue is well-know 
to be the main responsible for the regulation of the kinase. In particular, once phosphorylated, 
it inhibits the kinase activity of GSK3β (Cross et al., 1995). Molecularly, it happens because 
the phosphorylated N-terminus end of GSK3β occupies the site for the primed substrates, by 
acting as a pseudosubstrate, and by blocking in this way the catalytic activity of the kinase 
(Frame et al., 2001).  
A time course analysis of the phosphorylation status of Ser9 residue (p-GSK3β S9), in the 
U87MG/GSK3β+/+ cells, was performed, upon DMNQ or G5 treatments. A strong difference 
in terms of GSK3β activation was observed (Fig.15). In DMNQ-treated cells an early and 
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marked dephosphorylation of Ser9 was detected as soon as after 1 hour of treatment, which 
became stronger after 3 hours. At later time points (from 6 hours), GSK3β was again 
phosphorylated at Ser9, and subsequently inactivated. On the contrary, in G5-treated cells, the 
initial phosphorylation of Ser9 was modestly affected by G5 treatment throughout the period 
of the analysis.  
These results could explain the differential dependence of two necrotic insults from GSK3β, 
given the divergent responses of U87MG/GSK3β-/- cells to the two treatments.  
To support these data, we investigated the status of Akt activation, a main up-stream regulator 
of GSK3β activity. Once Akt is activated, it is able, by phosphorylating GSK3β on Ser9, to 
inactivate it (Cross et al., 1995; Alessi and Cohen, 1998). To this purpose, the Thr308 and 
Ser473 phosphorylation status of Akt (p-Akt T308 and p-Akt S473) were followed. 
Immunoblot analysis showed a correspondence between the decrease of the p-GSK3β S9 and 
the inactivation of Akt, given by an early dephosphorylation of Thr308, in response to the 
DMNQ exposure. In opposite, the phosphorylation of Ser473 was not strongly affected in 
response to DMNQ treatment (Fig.15).  
In the G5-treated cells, the phosphorylation status of Akt did not correspond with the GSK3β 
status, since an early and strong Akt activation was detected later 1 hour from the treatment. 
p-GSK3β S9 status was independent from the p-Akt T308. In contrast to the DMNQ, Thr308-
dependent activation of Akt was strongly involved during the G5 exposure (Fig.15).  
DMNQ treatment can elicit a profound re-organization of the mitochondrial network, which 
depends on Drp1 activities (Tomasella et al., 2014). 
To gain further insight into the intracellular effects supervised by GSK3β, in response to 
DMNQ treatment, U87MG/GSK3β+/+ and GSK3β-/- cells were analyzed for the integrity and 
morphology of mitochondrial network. In particular, Smac localization was studied, since it 
allows to monitor the mitochondrial morphology and the integrity of the outer mitochondrial 
membrane (OMM) (Lim et al., 2002; Newmeyer and Ferguson-Miller, 2003). By 
immunofluorescence analysis of the Smac localization, in the DMNQ-treated U87MG/
GSK3β+/+ and GSK3β-/- cells, it was noticed that in both cellular contexts (hence, in a GSK3β-
independent way), the mitochondria underwent fragmentation in response to DMNQ 
treatment (Fig.16A). Next, we evaluated the total levels of Smac in DMNQ-treated cells. The 
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Smac levels were clearly reduced in U87MG/GSK3β+/+ cells, whereas they were unaffected in 
the U87MG/GSK3β-/- cells (Fig.16B). Re-expression of GSK3β promoted the decrease of 
Smac protein. The degradation of Smac, in response to DMNQ, could be related to its release 
into the cytoplasm as consequence of the rupture of the OMM (Henderson et al., 2005). 
In fact, although the mitochondria of U87MG/GSK3β+/+ and GSK3β-/- cells present the same 
morphology upon the DMNQ exposure, the mitochondrial membrane potential (Δψm) was 
completely different. The cytofluorimetric measurements, using the probe TMRM, 
demonstrated that, in the U87MG/GSK3β-/- cells, the mitochondrial potential is well 
maintained, also after 24 hours of DMNQ treatment. By contrast, in U87MG/GSK3β+/+ cells a 
dramatic drop of the mitochondrial potential was measured in response to DMNQ (Fig.16C). 
TMRM probe was recording effectively the  Δψm of the treated cells, since the incubation with 
the mitochondrial uncoupler FCCP drastically reduced the TMRM fluorescence, given by the 
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Figure 15: Differential activated signaling pathways in DMNQ- 
and G5-treated U87MG/GSK3β +/+ cells. Comparative immunoblot 
analysis between U87MG GSK3β +/+ cells treated with DMNQ (30 
µM) or G5 (10 µM) for the indicated times. p-GSK3β S9, GSK3β, p-




Figure 16: Mitochondria state and functionality in the DMNQ-treated U87MG/
GSK3β+/+ and U87MG/GSK3β-/- cells. (A) Immunofluorescence of Smac subcellular 
localization and mitochondrial morphology in DMNQ-treated U87MG/GSK3β+/+ and 
U87MG/GSK3β-/- cells (30 µM for 24 hours). Cells were analyzed and imaged at confocal 
microscopy. (B) Comparative immunoblot analysis of lysates obtained from U87MG/
GSK3β+/+, U87MG/GSK3β-/- and U87MG/GSK3β-/- re-expressing GSK3β WT-GFP cells 
treated with DMNQ (30 µM) for the indicated times. Anti-Smac and anti-Tubulin (as 
loading control) antibodies were used. (C) Comparison of the Δψm in the U87MG/
GSK3β+/+, U87MG/GSK3β-/- and U87MG/GSK3β-/- re-expressing GSK3β WT cells after 
24 hours of DMNQ treatment (30 µM), measuring, by cytofluorimetric analysis, the 
TMRM fluorescence. Cells were incubated with TMRM (1 µM) for 30 minutes, then 
FCCP was added for 5 minutes (10 µM) before the FACS analysis. Data were from 3 






mitochondrial membrane depolarization. This effect was GSK3β independent (Fig.16C).    
3.6 Δψm dissipation and nuclear GSK3β translocation 
The oxidative stress and ROS generation mainly relies on the mitochondrial functions, 
influencing the cell viability. In fact, the mitochondrial respiratory chain is considered one of 
the major source for ROS generation and spreading, within a cell. At the same time, the 
mitochondria are very susceptible targets of the damaging effects related to the oxidative 
stress (Marchi et al., 2012). GSK3β is mainly a cytosolic protein, however its localization in 
other sub-cellular compartments, including the nucleus and the mitochondria, has been 
reported (Bijur and Jope, 2001; 2003). 
For these reasons, we investigated in vivo, the sub-cellular localization of GSK3β and the 
mitochondrial membrane potential in U87MG/GSK3β-/- cells re-expressing GSK3β WT-GFP, 
during the DMNQ exposure. A time-lapse experiment of 24 hours was performed, and the 
Δψm dissipation was evaluated by measuring TMRM fluorescence in single cells. In parallel, 
GSK3β localization was observed through the GFP. The integrity of the GSK3β-GFP probe 
during the period of analysis was verified by immunblot (Fig.17A). 
Single-cell imaging analysis of DMNQ-treated cells showed that the DMNQ treatment 
determines a gradual nuclear translocation of GSK3β, followed by Δψm collapse, cell 
detachment and death (Fig.17A). Measuring changes of the cytosolic TMRM fluorescence, 
and in parallel, of the nuclear/cytosolic GSK3β-GFP fluorescence ratio, in DMNQ treated-
cells, it was possible to appreciate that the kinetic of the kinase nuclear translocation is 
gradual and linked to the Δψm loss. Since the single cells depolarize at different times from 
DMNQ treatment, the potential collapse was set to time zero. With some peculiarities, 3 hours 
before Δψm  collapse, some nuclear accumulation of GSK3β can be appreciated (Fig.17B). 
On the contrary, the untreated cells were characterized by “physiological fluctuations” of the 
Δψm (Hüser and Blutter, 1999), and by a stable nuclear/cytosolic GSK3β-GFP fluorescence 
ratio, during all the recorded time. These data indicate that the nuclear translocation of 
GSK3β-GFP seems to be specifically caused by the DMNQ treatment and that it appears in a 




Figure 17: Nuclear translocation of GSK3β-GFP during DMNQ treatment and mitochondrial 
Δψm dissipation in single cells. (A) Frames of two U87MG/GSK3β-/- re-expressing GSK3β WT-
GFP cells, examined in B at the indicated times. Immunoblot analysis of lysates obtained from 
U87MG/GSK3β-/- re-expressing GSK3β-GFP cells during the DMNQ treatment (30 µM) at the 
indicates times. Anti-GSK3β and anti-actin (as loading control) antibodies were used. (B) Individual 
traces of TMRM fluorescence (in red) and of nuclear/cytosolic GSK3β WT-GFP fluorescence ratio 
(in green) in ten U87MG/GSK3β-/- re-expressing GSK3β-GFP cells, treated with DMNQ (30 µM) 
for 24 hours. (C) Individual traces of TMRM fluorescence (in red) and of nuclear/cytosolic 




The importance of discovery new therapeutic targets is dictated by the frequent appearance/
emergence of resistance, in cancer cells, to the pro-apoptotic chemotherapeutic agents. 
Chemoresistance represents one of the major causes of cancer therapy failure (Longley and 
Johnston, 2005).  
A promising therapeutic target is the UPS, including some of its components, such as the class 
of isopeptidases, known as DUBs. These enzymes are interesting targets since their inhibition 
can trigger different death pathways including a peculiar necrotic response in apoptosis-
resistant cancer cells (Fontanini et al., 2009). Moreover, during this thesis we have 
demonstrated that G5, a N-SII, can react with exposed cysteines present in additional proteins 
not limited to the catalytic site of isopeptidases (Ciotti et al., 2018). 
G5-treatment promotes the proteasome blockage and the accumulation of poly-ubiquitinated 
proteins (Aleo et al., 2006), which in turn determine a strong proteotoxic stress followed by a 
peculiar necrotic pathway, as confirmed through the work performed in this thesis (Tomasella 
et al. 2016). Beside the induction of proteotoxic stress, the molecular elements of the necrotic 
pathway elicited by G5 are still undefined.  
The final aim of this thesis was to better dissect the necrotic mechanism induced by this drug, 
by identifying the critical genes required for the process. To this aim, genome editing 
approaches, such as the CRISPR-Cas9 system and the RNA interference, were used in a 
glioblastoma cell line. 
The unbiased screening of the DECIPHER library, composed by 27500 shRNAs directed 
against 5000 signaling-involved genes, revealed that the Ser/Thr kinase GSK3β could play a 
role in the G5-elicited death pathway. 
Since GSK3β acts on more than 100 known substrates, it is considered one of the busiest 
kinase in most of the cells (Sutherland, 2011). GSK3β is an unconventional kinase because it 
shows some peculiar characteristics. It is constitutively active. Hence, environmental signals 
trigger its inhibition rather than its activation. Second its substrates have to be phosphorylated 
at the fourth amino acid at the C-terminal end of GSK3β consensus site to allow the GSK3β 
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action. The concept of primed substrates (Fiol et al., 1987). This cooperation process, between 
the pre-phosphorylation of the specific substrate by different up-stream kinases and the 
following binding by GSK3β, consents signaling integration from different pathways (Grimes 
and Jope, 2001). In fact, although GSK3β has been originally identified as an important 
regulator of glycogen metabolism (Embi et al., 1980), its contribution to different cellular 
processes, including: cell proliferation, gene expression, cellular morphology, neural 
development and plasticity, cell survival and cell death, is well established (Cohen and Frame, 
2001; Frame and Cohen, 2001; Doble and Woodgett, 2003; Jope and Johnson, 2004). Not 
surprisingly, GSK3β is also involved in a wide number of diseases, such as in the bipolar 
depression, Parkinson's disease, Alzheimer's disease, cardiovascular diseases, diabetes, 
inflammatory dysfunctions and cancer (Gao et al., 2012; Forlenza et al., 2012; Amar et al., 
2011).   
In the context of tumor, GSK3β has raised interest as a potential therapeutic target in different 
types of cancer. However, this possibility was complicated by the recent findings about 
controversial roles of GSK3β as tumor promoter or tumor suppressor in a context-dependent 
manner (McCubrey, 2014). 
GSK3β can act as a tumor suppressor modulating the phosphorylation of β-catenin and its 
subsequent proteasome-dependent degradation (Polakis, 2007). This activity has been well 
demonstrated in skin and breast cancers, in which the GSK3β inhibition promotes 
proliferation and tumorigenesis through the β-catenin stabilization (Leis et al., 2002; Farago et 
al., 2005; Armanious et al., 2010). On the contrary, a role for GSK3β as tumor promoter has 
been described in colon, pancreatic cancers, liver and ovarian cancers. In these contexts 
GSK3β is highly expressed and a correlation between its inhibition and anti-proliferative 
effects was described (Shakoori et al., 2005; Ougolkov et al., 2005; Zhou et al., 2012; Luo et 
al., 2009). In these type of tumors, which exhibit a pathological GSK3β over-expression, the 
kinase could be seen as a promising therapeutic target. Currently, more than 50 GSK3β 
inhibitors have been described and some of them are under clinical investigations not limited 
to cancer (Ougolkov and Billadeau, 2008; McCubrey, 2014). 
In the glioblastoma model, chosen for this thesis work, some findings suggest a pro-survival 
role for GSK3β, since its chemical inhibition decreased the cellular proliferation (Furuta et al., 
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2017) and promoted cell death by apoptosis (Kotliarova et al., 2008). Another study also 
revealed that GSK3β sustained the survival and proliferation of glioblastoma cells by 
counteracting apoptosis (Miyashita et al., 2009).  
On the opposite, our data indicate that GSK3β plays a pro-death role in glioblastoma cells in 
response to treatment with specific necrotic stressors. The effects were less pronounced in the 
case of the N-SII G5, but they were prominent in DMNQ-treated cells. Thus, given that 
DMNQ is a mitochondrial ROS generator, GSK3β could be a key kinase in the transducing 
the death signals triggered by oxidative stress. 
Our results suggest that GSK3β plays a minor role during G5-induced necrosis. We 
hypothesize that although G5 can induce some oxidative stress (Tomasella et al., 2016), the 
engagement of other stresses including protein misfolding (Tomasella et al., 2016; Chitta et 
al., 2015) renders the cells less dependent on GSK3β activities.   
If this hypothesis holds true, GSK3β mainly controls the oxidative stress-induced necrosis and 
much less the proteotoxic-induced cell death. Alternatively, it is also possible that other 
kinases, in cooperation with GSK3β, act in controlling the G5-induced pathway. Hence, the 
only absence of GSK3β, in the GSK3β KO clone, it is not sufficient to completely abrogate 
the necrotic response to G5.   
A contribution of GSK3β in oxidative-induced cell death was previously observed. An 
increased cellular survival following glutamate and hydrogen peroxide exposure was reported 
in the neuronal HT22 cells, when they were pharmacological inhibited for GSK3β (Schäfer et 
al., 2004). Another study described the GSK3β involvement in the ROS-mediated signals 
triggered by an array of redox stressors in the retinoblastoma mutated cells. The treatment 
with 4HPR (retinoid N-(4-hydroxyphenyl)retinamide), PEITC (phenylethyl isothiocyanate) 
and As2O3 (arsenic trioxide) affected the cell viability of Y79 cells, by inducing the inhibition 
of GSK3β. This inactivation favors the activities of survival pathways. An up-regulation of 
the anti-oxidant heme oxygenase (HO-1) and an augmentation in the glutathione (GSH) levels 
were reported. Furthermore, retinoblastoma and prostate cancer cells resistant to 4HPR were 
characterized by a sustained inhibition of GSK3β, HO-1 over-expression and high GSH 
levels, confirming the role of GSK3β in controlling cell death during acute oxidative stress 
(Venè et al., 2014).  
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Reports on a different cellular context, the DCLF-treated tubular epithelial cells, showed that 
the GSK3β inactivation was associated with sustained viability and the suppression of 
necrosis and apoptosis. DCFL (diclofenac) is a non-steroidal anti-inflammatory drug able to 
elicit oxidative stress. In response to this drug, the treated cells activated GSK3β and 
stimulated the opening of the mitochondrial permeability transition (MPT) pore. This event 
seemed positively controlled by cyclophilin D, which promotes the MPT pore opening. 
Cyclophilin D was phosphorylated by GSK3β on two amino acid residues: Ser118 and 
Ser190. Hence, the DCFL-induced GSK3β activation could determine cell death by triggering 
the opening of the MPT pores. The same cells treated by TDZD-8 and DCLF, an inhibitor of 
GSK3β, were characterized by attenuated swelling of mitochondria, MPT suppression, and 
reduced cell death (Bao et al., 2012).     
The involvement of GSK3β in the oxidative stress-induced necrosis is further strengthened by 
the observation that this kinase is promptly activated in response to DMNQ, as monitored by 
Serine-9 dephosphorylation in its inhibitory N-terminal domain. It occurs within 1 hour to 
reach the full activation after 3 hours. Concomitantly, we observed an inactivation of Akt, 
which is one of the most relevant up-stream kinase able to inhibit GSK3β (Cross et al., 1995; 
Alessi and Cohen, 1998). This event could permit to GSK3β to be activated by a specific 
phosphatase such as PP1 (Szatmari et al., 2005) in response to the oxidative stress, which in 
turn, dephosphorylating the Ser9, leading to its activation. Interestingly, in our shRNA 
screening among genes, which down-regulation favors survival in response to G5, the protein 
phosphatase 1 regulatory subunit 3A was found. 
The re-activation of Akt 6 hours later determines the GSK3β inhibition. Later from the 
DMNQ incubation, necrosis appears. This means that in this time interval GSK3β activates or 
inactive different substrates, so the outcome of cell death is not directly mediated by GSK3β, 
but by its substrates. It seemed that once GSK3β defines the cell fate, it can be inactivated. 
Alternatively, the inhibition of GSK3β could be manifested by cells that resisted to the 
oxidative crisis and survive.  
Regarding the phosphorylation status of Akt Ser473, it did not show a phosphorylation pattern 
as the Akt T308. Several studies showed that the Akt full activation depends on these two 
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critical residues, but a partial activation can be achieved by only the phosphorylation of T308 
(Alessi and Cohen, 1998; Alessi et al., 1996).  
In contrast to our results, a previous study showed that Akt is activated and phosphorylated on 
both T308 and S473 in an early and transient manner during the incubation with hydrogen 
peroxide in Jurkat cells, thus inactivating GSK3β (LaHair et al., 2006). These data are in line 
with the results obtained also in different cellular contexts (Huang et al., 2001; Howe et al., 
2002). They further reported that, the phosphorylation of Akt, and consequently GSK3β 
inactivation in response to the oxidative stress, plays an anti-apoptotic role, sustaining the 
cellular survival. Most probably, Akt inactivation and GSK3β activation, that we detected 
upon DMNQ exposure, could explain the role of the Akt/GSK3β axis in controlling the life/
death balance.  
An opposite response of Akt was reveled in the G5-treated cells. Here a strong 
phosphorylation of the T308 appeared in response to G5, as previously noted (Tomasella et., 
2014). The differences in Akt activation and in parallel the partial contribution of GSK3β to 
G5-induced cell death can explain the different behavior of U87MG/GSK3β KO clone to the 
two treatments.  
Generally, an enhanced oxidative stress can impair the mitochondrial state, influencing cell 
survival. Mitochondria can be considered as an important source of intracellular ROS 
producing cellular superoxide anion (O2−) and hydrogen peroxide (H2O2), and, concomitantly, 
them-self are a direct targets of the damaging effects of the produced ROS (Griendling and 
FitzGerald 2003). In this context, mitochondria undergo to evident fragmentation in response 
to oxidative stress (Wu et al., 2011; Iqbal and Hood, 2014). 
Regarding the mitochondria morphology, it was observed that they underwent fragmentation 
in response to the DMNQ treatment (Tomasella et al., 2014). We observed that this response 
is GSK3β-independent. By contrast, we showed that mitochondrial integrity and functionality 
is strongly dependent on GSK3β.   
Specifically, it is well know that the oxidative phosphorylation is ensured by complexes I to 
II, III and IV, which drives the proton translocation across the inner membrane to the 
intermembrane space, forming a proton gradient measured as mitochondrial membrane 
potential (Δψm) (Duchen and Surin et al. 2003; Chen, 1988). This gradient maintains all 
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cellular functions, by driving the production of ATP by complex V (ATP synthetase). The 
preservation of the mitochondrial membrane potential represents a vital parameter for the cell. 
Its complete lost or collapse in the majority of mitochondria within a cell can be considered a 
point of no-return from cell death (Green and Amarante-Mendes, 1998; Ichim et al., 2015). 
The collapse of Δψm, after the treatment with DMNQ is suppressed in absence of GSK3β 
activity.   
Curiously, in DMNQ-treated cells, some GSK3β translocates into the nucleus before the 
collapse of mitochondrial potential. GSK3β can translocate in the nucleus thanks to its 
bipartite nuclear localization sequence (NLS), which is normally hidden when GSK3β is 
complexed with interacting proteins in the cytosol. In a stimuli-dependent manner, GSK3β 
dissociates and the NLS drives the kinase into the nucleus. A previous study reported the 
nuclear moving of this kinase in the TNF-treated HeLa cells. They demonstrated that an anti-
apoptotic role of GSK3β seems to be exercised by the cytosolic form (Meares and Jope, 
2007). Another report described the GSK3β translocation as a consequence of different 
apoptotic stimuli, but independently from its Ser9 and Tyr216 phosphorylation status (Bijur 
and Jope, 2001). Interestingly, in a complete different context, the murine embryonic stem 
cells (mESCs), GSK3β was able to shuttle from the cytoplasm into the nucleus. Once Akt was 
activated, it promoted the cytosolic accumulation of GSK3β, its phosphorylation and 
inactivation. This means that activated GSK3β works in the nucleus and mediates the 
differentiation signal (Bechard and Dalton, 2009).  
In our case, the nuclear translocation of GSK3β occurs at a later step after DMNQ treatment. 
Further studies will be necessary to reveal the mechanisms controlling GSK3β translocation. 
Moreover, because the limited definition of the time-lapse analysis in vivo, a partial re-
localization of GSK3β at mitochondrial level, as described by Chiara et al., cannot be 
excluded (Chiara et al., 2012). 
In the literature it has been described the capability of GSK3β to exert some effects on gene 
expression, indirectly, by affecting several transcription factors and, directly, by modifying 
epigenetic mechanisms. Among the transcription factors known as GSK3β substrates, there 
are Fos/Jun AP-1, heat shock factor 1, myc, NF-kB, p53, STAT3, as well as many others 
(Grimes and Jope, 2001; Jope and Johnson, 2004). Regarding the involvement of GSK3β in 
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the epigenetic regulation, some evidences reported that GSK3β contributes to the regulation 
of some important histone modification, as the phosphorylation of histone 1.5 (Happel et al., 
2009) and histone 3 (Zhou et al., 2016). Moreover, this kinase can also act on the histone 
deacetylases (HDACs), by modulating the activity of HDAC3, and the degradation of 
HDAC4 (Bardai and D’Mello, 2011; Cernotta et al., 2011). A better investigation of the 
nuclear function played by GSK3β in the DMNQ response is necessary to understand in 
which way the cell death is carried out.  
To conclude, since the DMNQ has not a clinical use, the acknowledgment about the role of 
GSK3β in the oxidative stress response could be useful for those therapies in which the 
oxidative stress played a central role, as in the case of Photodynamic Therapy (PDT). PDT is 
able to induce oxidative stress using a photosensitizer and the correct light based on the 
absorption and emission spectra of the photosensitizer (Gomer et al. 1996). The PDT is under 
studies for several types of cancers and it could be possible to study the behavior of the 
U87MG/GSK3β KO cells in response to this type of treatment. If in the absence of the kinase, 
the cells are resistant to this type of treatment, the GSK3β expression in the cancer cells can 
be seen as a predictive factor of the therapeutic outcome. 
In addition GSK3β and oxidative stress seems to be involved in neurodegenerative disorders, 
including Alzheimer’s disease and Parkinson’s disease (Behl, 1997; Behl et al., 1997; 
Butterfield and Kanski, 2001; Halliwell, 2001; Jenner and Olanow, 1996; Moosmann and 
Behl, 2002). The central nervous system is an important target for this type of stress, mainly 
due to its consistent oxygen turnover. This could be the reason for which the oxidative stress 
can be considered as the cause of these pathologies. Since they are characterized by the lost of 
neural cells, signaling pathways able to protect these cells from the death induced by an 
excessive production of ROS are of interest. Working on GSK3β and its inactivation may 
provide a promising therapy for the prevention and treatment of these oxidative stress and 
aging-associated neurodegenerative diseases.  
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5. Materials & Methods  
5.1 Cell culture conditions and reagents 
The Human glioblastoma cell line Uppsala 87 Malignant Glioma (U87MG), the Human 
Embryonic Kidney cells 293 T1 (HEK293T1) and the Phoenix Amphotropic (AMPHO) were 
maintained at 37°C in 5% CO2 atmosphere in Dulbecco's Modified Eagle's Medium (DMEM, 
Sigma-Aldrich) supplemented with 10% Fetal Bovine Serum (FBS; Euroclone), glutamine (2 
mmol/L, Lonza), penicillin (100 U/mL) and streptomycin (100 µg/mL). The following 
chemicals agent were used: 4H-thiopyran-4-one, tetrahydro-3,5-bis[(4-nitrophenyl) 
methylene]-1,1-dioxide (G5; Aleo et al., 2006), 2,3-dimethoxy-1,4-naphthoquinone (DMNQ; 
Sigma Aldrich), Propidium Iodide (PI; Sigma Aldrich), DMSO (Sigma Aldrich), Tetramethyl 
Rhodamine Methyl-ester (TMRM, Scorrano et al., 1999), Bortezomib (LC Laboratories), 
TNF-related apoptosis-inducing ligand (TRAIL, Sgorbissa et al., 2011), carbonilcyanide p-
triflouromethoxyphenylhydrazone (FCCP, Sigma Aldrich). 
5.2 shRNA library: production, application and “hits” selection 
The DECIPHERTM shRNA lentiviral Human Module 1 (HM1) library (Cellecta Inc.) was 
provided by the DECIPHER Open Source RNAi Screening Project (http://
www.decipherproject.net/). The DECIPHERTM HM1 library was composed of 27500 shRNA 
sequences targeting 5,043 genes (5–6 shRNAs/mRNA). Among the targeted genes, members 
of major canonical and non-canonical signaling pathways were represented. Each shRNA was 
tagged with an unique 18 nucleotide sequence termed “barcode”, which permits the final 
identification after the Illumina Next-Generation Sequencing (NGS). The HTS3 (DECIPHER 
pRSI9-U6-(sh)-HTS3-UbiC-TagRFP-2A-Puro-dW) cassette of each shRNA contained the 
following elements: (i) U6 RNA polymerase III promoter, necessary to drive the shRNA 
expression, (ii) the specific and unique 18-nucleotide DNA barcode sequence, (iii) UbiC 
promoter responsible of red fluorescence protein (RFP) expression into the infected cells, (iv) 
the puromycin selection gene, and v) three different set of primers, two for the final barcode-
amplification PCR and one for the sub-sequential DNA sequencing.  
Lentiviral packaging was performed following manufacturer instructions (Cellecta Inc.). The 
HEK293T1 packaging cells were transfected with a solution given by 60 µg of the shRNA 
library and 300 µg of the packaging plasmid mix (psPAX2 and pMD2.G; Cellecta Inc.) in 
DMEM without serum or antibiotics, in the presence of Plus ReagentTM and LipofectaminTM 
(Life Technologies). HEK293T1 cells were incubated with this mix solution for 24 h. Viral 
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supernatant was collected at 48 h and 72 h after transfection, filtered through a 0.45 µm filter 
and concentrated using LentiFugeTM (Cellecta Inc.) following the manufacturer’s protocol. 
The concentrated lentiviral particles were re-suspended in 3 ml of PBS/10% FBS and stored 
at −80 °C. For the lentiviral titer estimation, the U87MG cells were seeded in a 12-well plate 
and, they were infected with 15 µl of thawed solution containing the lentivirus. After 24 
hours, these cells were harvested and the RFP positivity (corresponding to the infected 
shRNA+ RFP+ cells) was measured by fluorescence-activated cell sorting (FACS; Beckman 
Dickinson). Using a table providing by Cellecta, it was possible to calculate the Transduction 
Units of the solution containing the viral particles (TU/ml). One TU corresponds to one 
integration event in the target cells.  
Thus, using the following formula: 
TU/ml 
 
= (# 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑇𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛) ∗ [ MOI /
 
(𝑚𝑙 𝑜𝑓 𝑉𝑖𝑟𝑎𝑙 𝑆𝑡𝑜𝑐𝑘 𝑢𝑠𝑒𝑑 𝑎𝑡 𝑇𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛) ]
the calculated TU/ml was 440000 TU/ml.
Considering the obtained TU/ml, the MOI of 0,1, and the number of U87MG cells to infect, 
the volume of the viral stock to use for the infection was calculated by using the previous 
formula.   
The number of U87MG cells to infect was chosen considering that it should exceeded the 
complexity of the library of at least 200 times. For a library with 27500 shRNAs, the starting 
population should be at  least  5,5  million of  cells.  Regarding the multiplicity  of  infection 
(MOI), in a pooled shRNA screen, the starting number of cells should be 2-3 times more than 
the infecting viral particles to ensure that ~90% of the cells are infected with one shRNA-
carrying virus.  For all  these reasons,  33 millions of U87MG cells  were seeded. After the 
infection with the calculated viral volume, which was carried on for 48 hours, the shRNA+ 
U87MG cells were selected by adding Puromycin (2 μg/ml) at 37 °C for 72 hours. Later, the 
selected cells  were  treated with  G5 (2,5  μM) for  60 hours.  Genomic DNA (gDNA) was 
purified from the surviving cells using the QIAamp DNA Micro Kit (Qiagen) following the 
manufacturer’s instructions. Pooled barcodes were PCR-amplified starting from 100 μg of 
gDNA  and  they  were  identified  by  Illumina  High-throughput  (HT)  sequencing.  The 
conversion  of  raw  sequencing  data  into  summary  files,  that  include  annotation  for  each 
identified gene and the sequence frequencies, was performed using the barcode deconvoluter 
software (Cellecta Inc.). The target proteins, of whom at least two different shRNAs were 
represented by higher frequencies in comparison to the control luciferase shRNA frequencies, 
were defined “Hits” (NshRNAs ≥ 2). 
5.3 RNA interference 
The RNA interference (RNAi) was performed using the following siRNAs direct against: 
- Calpain-1 (CAPN1) (Santa Cruz Biotechnology); 
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- PP2AC (Fw 5’-GCAAGAGGUUCGAUGUCCAGUUACU-3’, Rv 5’-AGUAACUGGACA 
UCGAACCUCUUGC - 3’, Invitrogen); 
- GSK3β (Fw 5’-GCAUUUAUCGUUAACCUAA-3’, Rv 5’-UUAGGUUAACGAUA 
AAUGC - 3’, Sigma Aldrich); 
- control siRNA (Fw 5’-UAAGGCUAUGAAGAGAUAC-3’, 5’- GUAUCUCUUCAUA 
GCCUUA - 3’ (Sigma Aldrich).  
U87MG and U87MG BCLXL cells were transfected 24 hours after the seeding in Opti-MEM 
medium without antibiotics and containing Lipofectamine (Invitrogen) plus siRNAs (75nM). 
After 6 hours the medium was changed, and after 48 hours of silencing, the cells were treated 
with G5 or DMNQ for further 24 hours. In parallel, the RNA was extracted and the protein 
lysates were collected. As last step, the FACS analysis was performed on the down-regulated 
and treated cells. 
5.4 PI- and TMRM- assays 
For cytofluorimetric analysis, the cells were treated, one day after the seeding, with different 
concentrations of G5 (2.5 µM, 5 µM or 10 µM) or DMNQ (20 µM or 30 µM). DMSO was 
used for the untreated cells. Upon 24 hours of treatment, the cell death was measured adding 
PI (10 µg/ml) to the dead and living cells, which were resuspended in 200 µl of Phosphate-
Buffered Saline (PBS) for 5 minutes at room temperature. PI fluorescence was determined by 
FACS. Before to be analyzed, the untreated and treated cells were imaged with Leica DMi1 
microscope (10x objective).  
Data were represented as arithmetic mean of PI positivity percentage ± SD.  
For TMRM assay used to follow the Δψm, the cells were firstly DMNQ-treated (30 µM) for 24 
hours and they were incubated with TMRM (1 µM) for 30 minutes at 37 °C in 5% CO2 
atmosphere. FCCP (10 µM) was used to promote the mitochondrial membrane potential 
collapse and it was added 5 minutes before the TMRM fluorescence measure by FACS. Data 
were represented as arithmetic mean of TMRM positivity percentage ± SD. 
5.5 Cell lysis and Western Blotting 
The cellular lysis was performed using an SDS denaturing lysis solution, in which the 
Protease Inhibitor Cocktail (PIC), PhenylMethane Sulfonyl Fluoride (PMSF), Na3VO4 and β-
mercaptoethanol were added. The protein lysates were sonicated for 5 minutes at 4°C and 
they were boiled for 5 minutes. The denaturated proteins were loaded into a Sodium Dodecyl 
Sulfate (SDS) polyacrylamide gel to perform the electrophoresis. After the run, the proteins 
were transferred from the gel to a 0.2 µm-pore-sized nitrocellulose membrane. The aspecific 
sites of the membrane were blocked through the incubation with Milk 5% (Delikat Gramm), 
TrisHCl pH 7,5 1M, NaCl 5M, and Tween-20 (Riedel De-Haen) for 1 hour at room 
 53
Materials & Methods
temperature. Then the membranes were incubated with the specific primary antibodies for 4 
hours at room temperature or overnight at 4°C. The used primary antibodies were anti-
CAPN1 (1:1000; Santa Cruz Biotechnology), anti-PP2Ac (1:2000; Upstate, Lake Placid, NY), 
anti-actin (1:4000; Sigma Aldrich), anti-GSK3β (1:3000; Santa Cruz Biotechnology), anti-p-
GSK3β S9 (1:1000; Cell Signaling), anti-p-Akt T308, anti-p-Akt S473, anti-Akt (1:1000, 
1:3000, 1:1000; Cell Signaling), anti-Smac (1:2000; Henderson et al., 2005), anti-Casp2 
(1:3000; Foti et al., 2009), anti-HDAC4 (1:1000; Paroni et al., 2004), anti-tubulin (1:3000; 
Paroni et al., 2001). The same membranes were incubated with the horseradish peroxidase 
(HRP)-conjugated secondary antibody for 1 hour at room temperature. The used secondary 
antibodies were goat anti-mouse (Sigma Aldrich) or goat anti-rabbit (Sigma Aldrich). Finally, 
the blots were developed using Super Signal West Dura as recommended by the vendor 
(Pierce), impressing the signal on the photographic film through the produced 
chemiluminescence reaction. 
5.6 RNA extraction and qRT-PCR 
For the RNA extraction, the TRIzol (Molecular Research Center) was added to the cells. 
Then, the chloroform was added to the samples to separate the RNA from the DNA and 
proteins. The obtained RNA was precipitated using the isopropanol, and it was washed two 
times with ethanol 75% and resuspended in sterile water. The retro-transcription PCR (RT-
PCR) of 1 µg of extracted RNA was performed using a mix composed by First Strand Buffer 
(Invitrogen), dithiotreitol (DTT; 0,1 M; Invitrogen), dNTP Mix (2,5 mM; Thermo Scientific), 
oligo dT (20 µM; Eurofins Genomics), random primers (Promega), Rnase OUT Recombinant 
Ribonuclease inhibitor (30 U/µl; Invitrogen), and the Moloney murine leukemia virus reverse 
transcriptase (M-MLV; 200 U/µl; Invitrogen). The obtained cDNAs were analyzed by 
Quantitative Real Time PCR (qRT-PCR) using the SYBR Green technology (KAPA 
Biosystems). The studied genes were: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) and GSK3β. The obtained data 
were analyzed using the ΔΔCt method, considering HPRT and GAPDH as normalizer genes. 
All the reactions were performed in triplicate. 
5.7 Generation of GSK3β knock-out clone 
The generation of U87MG Knock-Out cells for GSK3β (termed GSK3β KO or GSK3β-/-) was 
achieved using the CRISPR/Cas9 technology. In particular, the single guide RNA (sgRNA) 
was designed using the bioinformatic tool “CRISPR design” (http://crispr.mit.edu/) and the 
sequence was the following: 
5’ - CCTTTGCGGAGAGCTGCAAG - 3’. 
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Firstly, this sgRNA was cloned into the lentiviral pLENTIV2 plasmid which contains the 
sequence of Cas9 wt, then the obtained plasmid was introduced in the U87MG cells through 
lentiviral infection. Specifically, the HEK293T1 packaging cells were transfected with the 
pLENTIV2-sgRNA-Cas9 wt, together with the Δ8.9 and VSV-G packaging plasmids, through 
the calcium phosphate method. The transfected cells were incubated for 48 hours at 37°C. 
After, the viral particles present in the supernatant were collected, diluted 1:1 with fresh 
medium, added with polybrene (8 µg/ml), filtered through 45 µm filters and used to infect 
U87MG cells. Later 24 hours at 37°C, the virus was removed and the infected cells were 
selected using the specific antibiotic (Puromycin 2 µg/ml). The selected U87MG cells were 
seeded 1 cell/well in 96-wells plates to promote the monoclonal growth of each cell. After 20 
days, the grown clones were screened through Western Blot. The found putative KO clone 
was further validated by Sanger sequencing. A screened clone resulted wt for GSK3β was 
used as control. The same protocol was followed to infect the U87MG cells with the empty 
pLENTIV2 plasmid expressing only Cas9 wt but not the sgRNA, in order to have an 
additional control clone. 
5.8 Cloning of GSK3β WT and KM  
To generate the U87MG cells expressing the two variants of GSK3β, the wild-type (WT) and 
the kinase-mutant (KM), the respective sequences were firstly cloned into pEGFP-N1 plasmid 
in order to add to the GSK3β sequence the Green Fluorescence Protein (GFP) tag at the C-
terminus end. Through a second step of cloning, the two sequences GSK3β WT-GFP and 
GSK3β KM-GFP were cloned into the retroviral plasmid pWZL-Neo.  
The coding sequence of GSK3β was amplified by PCR, using the following primers (Sigma): 
- AGATCTATGTCAGGGCGGCCCAG, as forward primer with in addition the restriction site 
for BglII; 
- GAATTCTGGTGGAGTTGGAAGCTGATG, as reverse primer with in addition the 
restriction site for EcoRI. 
The PCR products were ran on 1% agarose gel electrophoresis and the DNA molecules were 
extracted from the gel through the QIAquick Gel Extraction Kit (Qiagen). The used gels were 
produced in Tris-Acetate-EDTA (TAE) buffer 1X and the ethidium bromide was added in 
order to visualize the DNA. The extracted DNA was digested with the restriction enzymes 
BglII (Thermo Scientific) and EcoRI (Thermo Scientific) for 40 minutes at 37°C. The 
pEGFP-N1 plasmid was digested with the same restriction enzymes. The digested DNA 
fragments were ligated with the digested plasmid pEGFP-N1 in a ratio 3:1 by using the T4 
DNA Ligase (Thermo Scientific) and its specific 10x T4 DNA Ligase Buffer (Thermo 
Scientific) for 20 minutes at 24°C. Subsequently, STBL3 bacteria cells were transformed, 
plated onto Lysogeny Broth (LB)-agar plates and incubated overnight at 37°C. The grown 
colonies were picked from the plates, and incubated with LB overnight at 37°C. The day after, 
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the bacteria were harvested and the pEGFP-N1 plasmids were extracted using the Plasmid 
Plus Midi Kit (Qiagen), following the manufacturer’s instructions. After the control of the 
cloning, the same steps were repeated to clone the GSK3β WT-GFP and GSK3β KM-GFP into 
the retroviral plasmid pWZL-Neo. Therefore, the two sequences GSK3β-WT and GSK3β-KM 
from the pEGFP-N1 plasmids were amplified by PCR using the following primers (Sigma): 
- AGATCTATGTCAGGGCGGCCCAG as forward primer with in addition the restriction site 
for BglII; 
- CTCGAGTTACTTGTACAGCTCGTCC as reverse primer with in addition the restriction 
site for XhoI. 
Repeating the steps of extraction from the gel, digestion, and ligation, the GSK3β WT-GFP 
and GSK3β KM-GFP sequences were cloned into pWZL-Neo plasmids, which were used to 
transform STBL3 bacteria cells. These GSK3β-WT and GSK3β-KM constructs were used to 
perform the retroviral infection of the U87MG cells. 
5.9 Transfection and retroviral infection 
U87MG cells expressing BCL-XL, GSK3β-WT-GFP or KM-GFP constructs were generated 
by retroviral infection. Briefly, retroviral vectors were transfected in the AMPHO cells 
through the calcium phosphate method. After 48 hours, the viral supernatants were collected, 
filtered, supplemented with 8 µg/ml Polybrene, and combined with fresh medium in a ratio of 
1:1 in order to infect U87MG cells. The infection was maintained for 48 hours at 32°C and 
the selection with the specific antibiotic was applied: G418 (1000 µg/ml) for the selection of 
GSK3β WT-GFP and GSK3β KM-GFP expressing cells and Hygromycin (200 µg/ml) for the 
selection of BCL-XL expressing cells. 
The control cells were obtained infecting the U87MG cells with the two empty pWZL-Hygro 
and pWZL-Neo plasmids. 
5.10 Immunofluorescence  
U87MG/GSK3β+/+ and GSK3β-/- cells were fixed with 3% paraformaldehyde (PFA) and 
permeabilized with 0.5 % Triton X-100. The primary antibody was anti-Smac (Henderson et 
al., 2005), and the secondary antibody Alexa Fluor 546-conjugated anti-rabbit (Molecular 
Probes). Cells were imaged with a Leica confocal microscopy SP equipped with a 488 λ Ar 
laser and a 543 to 633 λ HeNe laser.   
5.11 Time-lapse confocal fluorescence microscopy 
U87MG/GSK3β-/- re-expressing GSK3β WT-GFP cells were seeded 200000 cells/glass-
bottom dish 35 mm and, the day after, they were incubated with the Δψm-sensitive dye 
TMRM (20 µM; Henderson et al. 2005) and with DMNQ (30 µM). After 1 hour of treatment, 
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the time-lapse analysis was performed. The imaging of the fluorescence relative to the 
GSK3β-GFP and TMRM was evaluated every 5 minutes for 24 hours using the time-lapse 
imaging system (Leica). The image analysis was obtained using the Leica Acquired Software 
X (LASX). For the Δψm analysis, the fluorescence of the mitochondria was evaluated drawing 
a region around the cell (Region Of Interest; ROI) and measuring the Mean fluorescence 
Intensity of TMRM (MITMRMcell). The fluorescence of the background (BKTMRM), which is 
another ROI located in a non-fluorescent region, was subtracted to the MITMRMcell and the 
obtained data was multiplied for the area of the cell (Areacell), according to the following 
equation: 
TMRM fluorescence (%) = (MITMRMcell- BKTMRM) * Areacell 
The same steps were followed for the untreated cells, which were not incubated with the 
DMNQ, but only with the TMRM. A similar calculation was used to quantify the increase of 
nuclear GSK3β-GFP fluorescence, according to the following formula: 
Nuclear GSK3β-GFP = (MIGSK3β-GFPnucl- BKGSK3β-GFP) * Areanucl /  
                                             (MIGSK3β-GFPcytosol- BKGSK3β-GFPcytosol) * Areacytosol 
5.12 Statistics 
Results were expressed as means ± standard deviations (SD) from at least three independent 
experiments. Statistical analysis was performed using the Student’s t-test of Excel software 
and p values represented as: * p < 0.05; ** p < 0.01; *** p < 0.005. 
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ABSTRACT
Relapse after treatment is a common and unresolved problem for patients 
suffering of the B-cell chronic lymphocytic leukemia (B-CLL). Here we investigated 
the ability of the isopeptidase inhibitor 2cPE to trigger apoptosis in leukemia cells in 
comparison with bortezomib, another inhibitor of the ubiquitin-proteasome system 
(UPS). Both inhibitors trigger apoptosis in CLL B cells and gene expression profiles 
studies denoted how a substantial part of genes up-regulated by these compounds 
are elements of adaptive responses, aimed to sustain cell survival. 2cPE treatment 
elicits the up-regulation of chaperones, proteasomal subunits and elements of the 
anti-oxidant response. Selective inhibition of these responses augments apoptosis 
in response to 2cPE treatment. We have also observed that the product of the ataxia 
telangiectasia mutated gene (ATM) is activated in 2cPE treated cells. Stimulation 
of ATM signaling is possibly dependent on the alteration of the redox homeostasis. 
Importantly ATM inhibition, mutations or down-modulation increase cell death in 
response to 2cPE. Overall this work suggests that 2cPE could offer new opportunities 
for the treatment of B-CLL.
INTRODUCTION
B-cell chronic lymphocytic leukemia (B-CLL) is 
the most prevalent leukemia in Western countries and it 
is characterized by accumulation of malignant cells in the 
blood, lymph nodes, spleen and bone marrow. B-CLL is 
a severe disease with heterogeneous clinical course and 
although new therapies have significantly prolonged the 
overall survival, most patients relapse [1]. Augmented 
expression of anti-apoptotic Bcl-2 family members and 
up-regulation of pro-survival pathways contribute to the 
resistant phenotype [1–5].
Among drugs tested for the ability to trigger 
apoptosis in B-CLL cells, inhibitors of the ubiquitin-
proteasome system (UPS) have raised some interest. 
Bortezomib, the first UPS inhibitor approved for the use 
in clinic, efficiently triggers apoptosis in in vitro cultured 
B-CLL cells [6, 7]. Unfortunately, clinical trials evaluating 
bortezomib in B-CLL patients were unsatisfactory [8]. 
Several constrains can explain this failure, including 
the chemical reaction between the boronate moiety of 
bortezomib and dietary flavonoids [9]. Furthermore 
bortezomib induces thrombocytopenia and neuropathy 
possibly due to proteasomal independent activities [10]. 
Hence, evaluating alternative compounds targeting the 
UPS for the treatment of B-CLL is of primary importance.
Small molecules characterized by the presence 
of a cross-conjugated α,β-unsaturated dienone with 
two sterically accessible electrophilic β-carbons can 
act as Michael acceptors to target nucleophiles, such 
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as cysteine residues [11–14]. Highly susceptible to 
these compounds are the isopeptidases, which contain 
a cysteine in the catalytic core. Isopeptidases include 
DUBs (deubiquitylases) and ubiquitin-like proteases. 
Although the presence of different groups, in addition to 
the pharmacophore, can enhance or limit the promiscuity 
of these compounds, we refer to them as partially-selective 
isopeptidase inhibitors (P-SIIs) [11–16].
P-SIIs are potent inducers of apoptosis and of 
additional types of cell death, particularly in cells 
showing extreme apoptotic resistance [17–19]. We have 
recently developed a PEG-conjugated P-SII, named 2cPE 
optimized for the in vivo delivery. 2cPE is a pro-drug 
version of G5 [11], which can be activated by secreted 
esterase and exhibits promising anti-neoplastic activities 
in vivo [20]. In this manuscript, we have investigated the 
effect of 2cPE against B-CLL cells, in comparison with 
bortezomib. Our results prove that induction of proteotoxic 
stress is a key aspect of 2cPE activity and discovered an 
unexpected contribution of ATM in influencing 2cPE-
induced apoptosis.
RESULTS
The UPS inhibitors bortezomib, G5 and 2cPE 
cause loss of viability of CD19+ B-CLL cells
Bortezomib and the isopeptidase inhibitor G5, or 
its PEGylated derivative 2cPE, induce loss of viability in 
primary CLL cells (Figure 1A and 1B). Cytofluorimetric 
analysis proved that, for all inhibitors, the loss of viability 
is largely caused by the induction of apoptosis, with only a 
minor fraction of the cells exhibiting markers (Annexin-V- 
and PI+) of primary necrosis (Figure 1C and 1D).
Gene expression profiles of B-CLL cells treated 
with the UPS inhibitors bortezomib and 2cPE
To explore whether bortezomib and 2cPE elicit 
similar or different biological responses, we performed 
microarray experiments in primary B-CLL cells. Leukemia 
CD19+ B-cells from 10 different patients were treated or 
not for 3, 6, 12 and 24 hours with 6nM of bortezomib 
or with 4μM of 2cPE. Under these conditions the two 
compounds induce equivalent levels of apoptosis, at 24 
hours. For the microarray analysis the 6 hours time-point 
was selected in order to observe early adaptive responses 
to the inhibitors and to exclude changes in mRNA 
expression depending on cellular demise. The clinical 
and prognostic features of each of the 10 primary CLL 
samples and their responsiveness in terms of apoptosis are 
described in Table 1.
Data analysis identified a list of common genes, 
which expression is influenced by both compounds. Venn 
diagrams (Figure 2A) illustrate that only few genes were 
commonly modulated by 2cPE and bortezomib in different 
patients (19 up-regulated and 15 down-regulated). Overall 
2cPE influences the expression of a wider number of genes 
compared to bortezomib, 169 and 95 genes respectively, 
including both up and down-regulated ones.
The vast majority of the commonly up-regulated 
genes encode for chaperones implicated in the regulation 
of protein folding (Figure 2B). A second group of genes 
comprises proteasome subunits. Interestingly among the 
commonly down-regulated genes, metabolic elements and 
components of signaling pathways can be found.
It is known that the level of proteasomal subunits 
can influence responsiveness to bortezomib treatment 
[21–23]. Hence, we compared changes in the expression 
levels of all proteasomal genes. Up-regulation of mRNAs 
encoding for several proteasomal subunits is a mark of 
the response to both inhibitors. This response was more 
pronounced in the case of bortezomib, whereas the down-
regulation of the immunoproteasome subunits PSMB8, 
PSMB9 and PSMB10 was comparable or even more 
evident in 2cPE treated cells.
The GO enrichment analysis for 2cPE and bortezomib 
regulated genes (Table 2) showed that the two drugs can elicit 
common but also distinct responses. Over-representations 
of processes such as protein folding, response to unfolded 
protein and response to organic substance characterize 
the genetic programs activated by 2cPE. Instead after 
bortezomib treatment, proteasome complex and regulation 
of E3 ligase activity are the most represented categories. 
Comparative analysis of the GO terms enrichment confirmed 
that the response to 2cPE treatment is strongly characterized 
by the up-regulation of chaperones, whereas the response 
to bortezomib is highly represented by UPS components 
(Supplementary Table S1).
Adaptive responses are engaged in B-CLL cells 
after 2cPE treatment
The microarray studies suggest that a substantial part 
of genes up-regulated in response to 2cPE are elements of 
adaptive programs aimed to sustain cell survival. These 
programs include the accumulation of new proteasomal 
units, to overcome its obstruction, the up-regulation of 
chaperones, to counteract misfolding and the potentiation 
of the anti-oxidant capabilities. In addition, 2cPE triggers 
also the down-regulation of some signaling pathways. To 
validate our studies we performed qRT-PCR analysis on 
four different genes, archetypes of the adaptive responses 
engaged by 2cPE. Three selected genes were up-regulated: 
GCLM, HMOX1, SQSTM1/p62, whereas the fourth gene, 
LCK, was down-regulated. Supplementary Table S2 shows 
the average fold induction and the correlation analysis, 
respect to the induction of apoptosis in the different 
B-CLL, for these genes.
GCLM (glutamate cysteine ligase modifier) encodes 
for the component of the glutamate cysteine ligase (GCL), 
the enzyme responsible for glutathione (GSH) synthesis. 
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Both subunits were increased after 2cPE treatment. The 
heme oxygenase-1 (HMOX1) encodes for an ubiquitous 
enzyme that supervises cytoprotective responses to toxic 
insults [24]. SQSTM1/p62/sequestosome encodes for a 
scaffold protein functioning as signaling hub in different 
pathways including autophagy [25]. Finally, LCK encodes 
for the T-cell-specific member of the Src family of tyrosine 
kinase, which is also expressed in B-CLL [26]. The qRT-
PCR analysis corroborated the regulation of these genes 
in response to 2cPE treatment (Supplementary Figure S1).
We next confirmed these data in human chronic 
B-cell leukemia, MEC-1 cells. The 2cPE pro-drug and 
its unconjugated version, 2c induce comparable levels of 
cell death (Figure 3A), thus indicating that this cell line 
Figure 1: Pro-apoptotic activity of bortezomib, the P-SII G5 and its pro-drug derivative 2cPE in primary B-CLL 
cells. A. Primary B-CLL cells viability following treatment with escalating doses of G5 or bortezomib for 24 hours as indicated. Cell 
viability was calculated as percentage of cells negative to PI and Annexin V staining after cytofluorimetric analysis. B. Flow cytometry 
analysis for apoptotic markers (Annexin V/PI) in order to define the type of cell death. Primary B-CLL cells were treated with the indicated 
concentrations of bortezomib or G5 for 24 hours. C. Primary B-CLL cells viability following treatment with escalating doses of 2cPE for 
24 hours as indicated. Cell viability was calculated as the percentage of cells negative to PI and Annexin V staining after cytofluorimetric 
analysis. D. Flow cytometry analysis for apoptotic markers (Annexin V/PI) in order to define the type of cell death. Primary B-CLL 
cells were treated with the indicated concentrations of 2cPE for 24 hours. Columns, mean loss of viability + SD. *=p<0.05; **=p<0.01; 
***p=<0.005.
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secretes the esterase PLA2G7 [20]. 2c and 2cPE induced 
cell death was apoptotic, as confirmed by the caspase-
dependent proteolytic cleavage of the death substrate 
GAS2 (Figure 3B) [27]. In MEC-1 cells, similarly to 
primary B-CLL cells, 2cPE treatment up-regulates the 
expression of HMOX1, GSLM as well as of SQSTM1 and 
down-regulates LCK mRNA levels (Figure 3C).
HMOX1, GCLM and SQSTM1 are components 
of the cytoprotective response to oxidative stress and, 
likewise other genes induced after 2cPE treatment, they 
are under the control of the transcription factor NRF2 [28, 
29]. Figure 3D proves that 2cPE treatment augmented 
NRF2 levels in MEC-1 cells.
Inhibition of the adaptive responses elicited by 
2cPE and effects on cell death
Several of 2cPE differentially expressed genes 
(DEGs) boost adaptive responses devoted for sustaining 
cell survival. Hence, suppressing these adaptive responses 
should potentiate apoptosis in response to 2cPE. To verify 
this hypothesis we co-treated MEC-1 cells with 2cPE 
in combination with buthionine sulfoximine (BSO), a 
selective inhibitor of γ-glutamylcysteine synthetase, or 
with the geldanamycin derivative 17-AAG, an inhibitor 
of HSP90. BSO alone was unable to trigger cell death 
but at highest doses it potentiated the pro-death effect of 
2cPE, as scored by both PI positivity and caspase activity 
(Figure 4A). When the ROS generator DMNQ was 
used, as positive control, the cooperative effect of BSO 
was more evident (Figure 4A). Treatment with 17-AGG 
alone induces apoptosis in approximately 30% of cells, 
independently from the applied dose. When MEC-1 cells 
pre-incubated with escalating doses of 17-AGG were co-
treated with 2cPE, cell death as well as the intensity of 
caspase activation, were significantly augmented (Figure 
4B). Similarly, also bortezomib induced cell death was 
augmented in the presence of the HSP90 inhibitor (Figure 
4B).
Down-regulation of LCK expression might be an 
important event for the pro-apoptotic activity of 2cPE. 
Also in this case treatment with an LCK inhibitor (LCKi) 
might exhibit an additive effect with 2cPE. Figure 
3C evidences that co-treatment with 2cPE and LCKi 
potentiates apoptosis and caspase activation in response 
to 2cPE.
Markers of responsiveness to 2cPE treatment
The apoptotic responsiveness of B-CLL cells from 
the different patients to 2cPE is heterogeneous (Table 1). 
Some cells are highly susceptible and others are resistant. 
Hence, we decided to use the pattern of all DEGs in all 
patients to discover markers of 2cPE responsiveness. The 
lists of DEGs were fused and used to extract the values 
of single patient differences (fold changes >1.5 <-1.5; 
P values <0.05). An unsupervised clustering analysis 
was performed and the results are presented as heat map 
(Figure 5). The apoptotic responsiveness of the different 
leukemic B-cells is displayed by a colour code. The 
Table 1: Clinical characteristics, apoptotic response, mutational status and genetic alterations of the included 
patients
code Sex/age IGHV FISH RAI stage CD38 2cPE Bortezomib
LL300 F/79 U 13q- II NEG 88 89
LLC122 M/66 U 11q- 0 POS 15 59
LLC195 M/69 U 11q-; 13q- II POS 2 86
LLC351 M/67 U 17q-; 13q- I POS 81 92
LLC270 M/73 U 11q- II POS 17 65
LLC4 F/73 M * I NEG 82 81
LLC305 M/56 M Normal 0 NEG 75 54
LLC366 F/69 * 13q-; 12+; p53 mut 0 POS 45 77
LLC37 F/79 M 13q- II NEG 8 38
LLC43 M/83 M 12+ I POS 68 82
 Apoptosis at 24 hours (%)
Note: The gender of the patients, the IgHV mutational status (U=unmutated, M= mutated), CD38 expression (POS = 
positive for CD38 expression; NEG = negative CD38 expression), the cytogenetic alterations observed and the % of 
apoptosis after 24 of treatment with the indicated drugs for each patient sample are shown. 
* indicates that the status of a specific characteristic for a patient is unknown.
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Figure 2: mRNA expression profiling of bortezomib and 2cPE treated B-CLL cells. A. Venn diagram of commonly down 
(green) and up-regulated (blue) genes (fold changes >1.5; P values <0.01) using the paired t-test, in leukemic B-cell from 10 different 
patients after 2cPE and bortezomib treatments. B. List in alphabetic order of the commonly up- and down-regulated genes in leukemic 
B-cells form the different patients in response to 2cPE and bortezomib treatments (mRNA fold changes >1.5; <-1.5). In the heat map 
positive values are displayed in blue and negative in dark green. A colour code was selected to illustrate the fold changes. C. mRNA fold 
changes of the different proteasomal components after 2cPE and bortezomib treatments as indicated by the different colours.
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hierarchical clustering evidences a strong correlation 
between the magnitude of changes in DEGs and the 
induction of cell death. In the case of 2cPE treatment, with 
the exclusion of patient LLC37, all B-CLL cells responsive 
to 2cPE in terms of apoptosis, cluster together and show 
elevated fluctuations of DEGs. On the other side, B-CLL 
cells, which are resistant to 2cPE treatment evidence 
fewer transcriptional changes and cluster together. The 
only exception concerns leukemic cells of patient LLC37, 
which are resistant to 2cPE treatment but cluster together 
with responsive cells. Interestingly, LLC37 cells are also 
partially resistant to bortezomib.
Resistance to 2cPE induced apoptosis in B-CLL 
cells from patients LLC122, LLC195 and 
LLC270
The resistance to 2cPE-induced apoptosis, 
observed in some leukemia B-cells (LLC122, LLC195 
and LLC270) is tightly correlated to much lower 
variations in the transcriptome. This failure could arise 
from an incapability to process the pro-drug 2cPE in the 
extracellular environment, as observed in certain cancer 
cells [20]. mRNA expression levels analysis of PLAG7, 
the secreted esterase responsible for 2cPE pro-drug 
maturation, excludes this hypothesis (Supplementary 
Figure S2).
Alternatively, resistance to 2cPE could arise from 
a common mRNA signature, as generated during disease 
progression, through the accumulation of peculiar 
genetic alterations. This signature should predict drug-
responsiveness. To verify this possibility, we performed 
hierarchical gene clustering analysis, of gene expression 
profiles of untreated B-CLL cells from all patients. Figure 
6A shows that, the B-CLL cells of the three patients 
resistant to 2cPE treatment cluster together. Next, a 
standard t-test was performed to rank DEGs between 2cPE 
unresponsive (n3) and the responsive leukemia cells (n7) 
(Figure 6B). The ATM gene provided the best score (P 
value 2.9306E-005; fold change -1.87). In accordance, 
all three patients-derived B-CLL cells display the 11q 
deletion, which affects the ATM locus [30]. Other two 
genes, NPAT and CUL5 lie in the same chromosome 
region and they also scored a significant reduction in 
terms of expression in the non-responsive patients (P 
value 0.0035; fold change -1.69 and P value 0.0020; fold 
change -1.64, respectively).
Table 2: GO-Terms enrichment analysis
Gene enrichment analysis in 2cPE treated primary B-CLL cells
GO-Term Count % p Value Benjamini FDR Fold Enr
GO:0006986~response  
to unfolded protein 13 8,33 1,66E-12 2,67E-09 2,78E-09 19,82
GO:0051789~response  
to protein stimulus 13 8,33 3,90E-07 1,96E-07 4,08E-07 13,15
GO:0050865~regulation 
of cell activation 14 8,97 7,16E-09 3,84E-06 1,20E-05 8,66
GO:0010033~response  
to organic substance 25 16,02 3,11E-08 1,25E-05 5,21E-05 3,75
GO:0006457~protein 
folding 13 8,33 7,73E-08 1,75E-05 0,00013 7,94
GO:0042981~regulation 
of apoptosis 25 16,02 2,38E-07 4,80E-05 0,0004 3,37
Gene enrichment analysis in Bortezomib treated primary B-CLL cells
GO-Term Count % p Value Benjamini FDR Fold Enr
GO:0000502~proteasome 
complex 14 15,73 4,31E-18 5,26E-16 4,97E-15 42,52
GO:0051351~positive 
regulation of ligase 
activity
15 16,85 1,35E-18 1,16E-15 2,09E-15 37,56
GO:0043161~proteasomal 
protein catabolic process 15 16,85 1,91E-16 1,91E-14 3,44E-13 26,88
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Figure 3: Adaptive responses elicited by 2cPE in MEC-1 cells. A. Induction of cell death in MEC-1 cells after treatment for the 
indicated times with 2c (2μM) or 2cPE (4μM). Cell viability was calculated as percentage of cells positive to PI staining using cytofluorimetric 
analysis. B. Caspase-dependent processing of the death substrate Gas2 in MEC-1 cells treated for the indicated times with 4μM of 2cPE. 
Cellular lysates were generated and subjected to immunoblot analysis. Antibodies anti-Gas2 and anti-actin (as loading control) were used. 
C. Time-course analysis of HOMX, GCLM, SQSTM and LCK mRNA expression levels. MEC-1 cells were treated 4μM of 2cPE for the 
indicated times and the mRNA levels were monitored by qRT-PCR. All reactions were done in triplicate. D. Immunoblot and densitometric 
analysis of NRF2 levels in MEC-1 cells treated for the indicated times with 4μM of 2cPE. Cellular lysates were generated and subjected 
to immunoblot analysis using the indicated antibodies. Data were from 2 experiments. Columns, mean loss of viability + SD. *=p<0.05; 
**=p<0.01; ***p=<0.005.
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Since ATM is an important signaling molecule, 
we decided to study whether this kinase is activated in 
response to 2cPE. Figure 7A demonstrates that the ATM 
pathway is activated in response to 2cPE, as proved by 
the phosphorylation of the ATM substrates KAP1, Smc1, 
Chk2 and p53. The 2cPE-mediated activation of ATM 
prompted us to evaluate the induction of DNA double-
strand breaks. Different concentrations of etoposide 
were used to induce DSBs and ATM activation. 4μM 
of 2cPE and 2.5/5 μM of etoposide elicited ATM 
activation at comparable intensities, as scored by KAP1 
phosphorylation (Figure 7B). A robust increase of γH2AX 
positivity (a marker of DSBs) can be appreciated in cells 
treated with 2.5 or 5 μM of etoposide. By contrast, only a 
modest but significant increase in γH2AX positivity was 
triggered by 2cPE treatment (Figure 7C). We confirmed 
these data by a time-course analysis. Again a modest, 
compared to etoposide, but significant increase in γH2AX 
was detectable in 2cPE treated cells at 6 hour (Figure 7D).
Next we investigated the contribution of ATM in 
2cPE-induced gene expression changes. Inhibition of 
the ATM kinase using the specific inhibitor KU-55933 
did not influenced the 2cPE-mediated up-regulation 
of GCLM, HOMX, SQSTM1 and the down-regulation 
Figure 4: Interfering with the different adaptive responses elicited by 2cPE augmented the apoptotic response. A. MEC-
1 cells were pre-treated with the indicated concentrations (μM) of BSO, for 24 h. Next, 2cPE (1μM), DMNQ (20μM) were added for further 
24 h. B. MEC-1 cells were pre-treated with the indicated concentrations (μM) of 17-AAG for 1 h. Next, 2cPE (1μM), bortezomib (0.5 μM) 
were added for further 24 h. C. MEC-1 cells were pre-treated with the indicated concentrations (μM) of LCKi for 16 h. Next, 2cPE (1μM), 
bortezomib (0.5 μM) were added for further 24 h. Cell death was scored by PI staining using cytofluorimetric analysis and caspase activity 
was measured in parallel. Columns, mean (n = 3); bars, SD. *=p<0.05; **=p<0.01; ***p=<0.005.
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of LCK (Figure 7E). Surprisingly, when the effect on 
cell survival was evaluated, the ATM inhibitor strongly 
potentiated apoptosis in response to 2cPE (Figure 8A). 
To confirm this result we used ataxia telangiectasia (AT)-
derived lymphoblastoid cell lines (AT-LCLs) WT or 
lacking ATM protein expression, due to the homozygous 
mutation AT-52RM [31]. Figure 8B illustrates that cells 
lacking ATM expression are more sensitive to death 
induced by 2cPE treatment. Finally, we also generated 
MEC-1 cells with down-regulated ATM expression 
after lentiviral infections with a specific shRNA (Figure 
8C). MEC-1 cells with down-regulated ATM were 
more susceptible to apoptosis after 2cPE treatment 
(Figure 8D).
Figure 5: Resistance to 2cPE induced apoptosis correlates with the magnitude of changes in DEGs. DEGs induced by 
2cPE or bortezomib treatments in B-CLL cells were hierarchically clustered as described in the material and methods. In the heat map 
up-regulated genes are displayed in blue and down-regulated genes in dark green. A colour code was used to represent the apoptotic 
responsiveness to 2cPE and bortezomib of the different B-CLL cells. Apoptosis >75% (dark green); apoptosis between 46-74% (light 
green) apoptosis <20% (grey) apoptosis <10% (black).
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Figure 6: ATM and the resistance to 2cPE. A. Hierarchical clustering of gene expression profiles of untreated B-CLL cells from the 
different patients. A colour code was used to represent the apoptotic responsiveness to 2cPE and bortezomib of the different B-CLL cells. 
Apoptosis >75% (dark green); apoptosis between 46-74% (light green) apoptosis <20% (grey) apoptosis <10% (black). B. 10 top DEGs in 
untreated B-CLL cells from patients LLC122, LLC195 and LLC270 compared to the untreated leukemia cells, responsive to 2cPE, from all 
other patients. DEGs were ranked for P value.
Figure 7: 2cPE activates ATM signaling. A. Activation of the ATM signaling pathway in response to 2cPE treatment. Cellular 
lysates were generated at the indicated time points and subjected to immunoblot analysis. The detected proteins and their phosphorylated 
forms are indicated. Actin was used as loading control. B. Immunoblot analysis comparing ATM activation in response to etoposide and 
2cPE. KAP1 phosphorylation was used as read-out for ATM activation. MEC-1 cells were treated for 6 h with the indicated concentrations 
of the two drugs. C. Quantitative cytofluorimetric analysis of γH2AX positivity as marker of DNA damage induction. MEC-1 cells were 
treated for 6 hours with the indicated concentrations of the two drugs. D. Time-course of γH2AX positivity by quantitative cytofluorimetric 
analysis. MEC-1 cells were treated for the indicated hours with 4μM of 2cPE or 2.5μM of etoposide. E. Time-course analysis of HOMX, 
GCLM, SQSTM and LCK mRNA expression levels in MEC-1 cells treated with 4μM of 2cPE in the presence of the ATM inhibitor KU-




Although bortezomib has proved inefficacy for 
the treatment of CLL patients [8], the UPS represents a 
promising therapeutic target and new UPS inhibitors are 
under evaluation [32–34]. In this manuscript we have 
demonstrated that 2cPE triggers apoptosis in B-CLL cells 
and activates multiple transcriptional programs.
The vast majority of DEGs associated to 2cPE 
and bortezomib treatments encode for elements of 
stress response pathways, aimed to sustain cell survival. 
Interfering with such adaptive pathways potentiates the 
pro-death effect of 2cPE. This discovery could help to 
improve the anti-neoplastic efficiency of these molecules, 
by applying selective co-treatments.
Interestingly 2cPE is a stronger inducer of 
proteotoxic stress compared to bortezomib. Proteotoxic 
stress is emerging as an attracting druggable response. 
Malignant cells exhibit higher levels of proteotoxic 
stress, as a consequence of their higher proliferative and 
mutational status [35–38]. This peculiarity renders cancer 
cells more dependent on the UPS and more vulnerable 
Figure 8: ATM inhibition strengthens apoptosis induced by 2cPE. A. MEC-1 cells were pre-treated for 1 hour with KU-55933 
(10μM). Next, 2cPE (2μM) or camptothecin (CTP) (50μM) were added for further 20 h. Cell death was calculated as percentage of cells 
positive to PI staining using cytofluorimetric analysis. B. LCL cells WT or AT-52 mutated were treated for 22 h with 2μM of 2cPE. Cell 
death was scored by PI staining using cytofluorimetric analysis. C. ATM mRNA levels in MEC-1 cells expressing the shRNA against ATM 
or the control, as generated by two distinct lentiviral infections. D. MEC-1 cells with down-regulated ATM expression generated after two 
distinct infections (A and B) and control cells were treated with 2cPE (0.5μM) for 6 h. Cell death was calculated as percentage of cells 
positive to PI staining using cytofluorimetric analysis. Columns, mean (n = 4); bars, SD. *=p<0.05; **=p<0.01; ***p=<0.005.
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to its inhibitors or to inducers of proteotoxic stress [39, 
40]. We propose that 2cPE and similar compounds are 
efficient anti-neoplastic drugs in vivo, because they elicit 
a vicious cycle, by triggering proteotoxic stress in cancer 
cells, which already exhibit high level of such stress. By 
contrast, 2cPE-induced proteotoxic stress is manageable 
in normal cells, thus explaining the absence of general 
toxicity in vivo [40–42]. It is possible that 2cPE and 
similar compounds, in addition of targeting the catalytic 
cysteine of isopeptidases, react with and consume the 
glutathione pool, thus provoking oxidative-stress. In fact, 
NRF2 is activated and the GSH regenerating system is up-
regulated in response to 2cPE. Moreover, pre-treatment 
of G5 with N-acetylcysteine completely abrogates its 
apoptotic activity (data not shown).
Because of the heterogeneity of this disease [43], 
some leukemia cells are resistant to 2cPE treatment. 
Gene expression profile analysis indicates two different 
conditions of resistance. In the first case, cells display 
overt changes in DEGs associated to 2cPE (patient 
LLC37). In the second case, which comprises leukemia 
cells from patients LLC122, LLC195 and LLC270, DEGs 
changes are dramatically reduced.
The components of the apoptotic machinery in 
LLC37 cells, (BCL2 family members and caspases) do not 
evidence alterations in their expression (data not shown). 
Hence, currently we cannot explain the origin of such 
resistance. Importantly, LLC37 cells were analogously 
resistant to bortezomib.
In leukemia cells from patients LLC122, LLC195 
and LLC270, resistance is not due to deficit in pro-drug 
maturation, as recently observed in other cancer cells [20]. 
Hierarchical gene clustering analysis of the different patient-
derived B-CLL cells and the presence of the 11q deletion 
suggested that ATM could be a candidate for such resistant 
phenotype. The ATM kinase has a well-defined role in 
sensing DNA double-strand breaks (DSB) and transducing 
downstream signals that activate the DNA repair and the 
cell cycle checkpoint machinery [44]. Notably, the ATM 
signaling pathway was stimulated by 2cPE.
ATM is also activated by oxidative stress, through 
a mechanism distinct to that of activation by DNA breaks 
[45]. The activation of the anti-oxidants response and the 
feeble appearance of DSBs in 2cPE treated cells, suggest 
that a perturbed redox balance might be responsible for 
ATM activation [46]. In an unexpected manner, ATM 
inhibition reinforced apoptosis in 2cPE treated cells. 
Hence, ATM cannot be responsible for the apoptotic 
resistance to 2cPE. Although we do not have an explanation 
for such resistance, our results disclose a new opportunity 
for testing 2cPE in cancer cells that have accumulated 
mutations in ATM, in p53, or in both genes [47, 48].
In conclusion we have demonstrated that 2cPE 
triggers pleiotropic cellular stresses. At first glance 
induction of multiple stresses does not seem to be 
attractive for the selective elimination of neoplastic cells, 
however several recent reports about the effectiveness in 
animal models of this class of compounds [12, 14, 15, 
20] justify further studies to improve their anti-neoplastic 
activities.
MATERIALS AND METHODS
Patients, cell separation and culture conditions
The ethic approval for our study was obtained from 
ethic committee of ‘‘Regione Veneto”: (Prot.n. 2662P). We 
obtained peripheral blood from 10 patients that satisfied 
standard morphological and immunophenotypic criteria 
for CLL according to the guidelines of the International 
Workshop on Chronic Lymphocytic Leukemia IWCLL 
[49]. No patient was previously treated with bortezomib or 
other proteasome inhibitors. Peripheral blood mononuclear 
cells (PBMCs) were isolated as previously described [50]. 
All samples utilized had a CD19+ B-cell content greater 
than 95%. Purified cells were cultured in RPMI-1640 
medium supplemented with 10% heated inactivated fetal 
calf serum (FCS; Invitrogen, Paisley, UK). Human chronic 
B-cell leukemia, MEC-1 cells and EBV-immortalized 
lymphoblastoid cell lines (LCLs) WT and AT52RM and 
compound heterozygous mutations 7626 C→T/8365 del 
A, were grown under similar conditions. Mediums were 
supplied with heated inactivated fetal calf serum (FCS; 
Sigma Aldrich), penicillin (100 U/mL), glutamine (2 
mmol/L), and streptomycin (100 μg/mL).
Reagents and antibodies
Chemicals used were: bortezomib (LC 
Laboratories), 2,3-dimethoxy-1,4-naphthoquinone 
(DMNQ), Propidium Iodide (Sigma Aldrich), buthionine 
sulfoximine (BSO), 7-cyclopentyl-5-(4-phenoxyphenly)-
7H-pyrrolo[2,3-d]pyrimidin-4-amine LCK inhibitor 
(LCKi), 17-(Allylamino)-17-demethoxygeldanamycin 
(17-AAG) (Cayman Chemicals), ATM inhibitor (KU-
55933) (Abcam Biochemicals), 2c ((E)-3,5-Bis[(p-
nitrophenyl)methylidene]-4-hydroxycyclohexanone), 
2cPE ((E)-3,5-Bis[(p-nitrophenyl)methylidene]-4-
oxocyclohexyl polyethyleneglycol succinate). Primary 
antibodies used were: anti-phospho-Ser139 H2A.X, 
anti-pKAP-1/TIF1β Ser824 and anti-KAP1/TIF1β (Cell 
Signaling), anti-actin (a2066 Sigma) anti-NRF2 (Santa 
Cruz Biotechnology).
RNA expression array and data analysis
Total RNA was isolated using RNeasy Mini 
kit (Qiagen). RNA samples concentration and purity 
(assessed as 260/280 nm and 260/230 nm ratios) were 
evaluated by NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies; Wilmington, DE), while 
RNA integrity was assessed by using the Agilent 
2100 Bioanalyzer (Agilent Technologies; Waldbrunn, 
Germany). For gene expression profiling (GEP) cDNA 
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synthesis and biotin-labeled target synthesis were 
performed using the GeneAtlas 3′ IVT Express Kit 
according to the protocol supplied by Affymetrix. The 
HG-U219 Array Strips (Affymetrix; Santa Clara, CA) 
hybridization, staining, and scanning were performed 
by using the GeneAtlas Platform. All the GEP data 
have been deposited in the NCBI's Gene Expression 
(GEO) public repository http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?token=kbapyckufpcdxwh&ac
c=GSE74514. Data analysis was performed using the 
paired t-test as previously described [51]. P values were 
adjusted for multiple testing using the False Discovery 
Rate method. Differentially expressed genes (DEGs) 
were selected based on fold change >1.5 and <-1.5 fold 
and P values <0.05. The analysis of Gene Ontology 
terms was performed using the DAVID server. DEGs 
in response to 2cPE or bortezomib were clustered using 
hierarchical clustering by computing the Euclidean 
distance and applying the complete linkage method. 
For the hierarchical clustering of the gene expression 
profiles of B-CLL cells from different patients before 
drug-treatment the average linkage method was used.
RNA extraction and qRT-PCR analysis
RNA was extracted using Tri-Reagent (Molecular 
Research Center) and retrotranscribed by using 100U of 
Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). The primer sequences used are available 
upon request. Quantitative reverse transcription-PCR 
(qRT-PCR) analyses were performed using Bio-Rad 
CFX96 and SYBR Green technology. HPRT and GAPDH 
were used as normalizer genes. All reactions were done 
in triplicate. Data were from al least 3 experiments ± SD.
Caspase activation assays and cytofluorimetric 
analysis
Analysis of caspase-3 activation was performed 
using Caspase-3 fluorescent assay kit (Cayman chemical). 
For quantification of cell death, cells were re-suspended 
in 500 μL of PBS and stained with propidium iodide 
(PI). Fluorescence was determined with a FACScan™ 
(Beckman Dickinson). To detect H2AX phosphorylation 
cells were fixed in paraformaldehyde 3% for 20’ at room 
temperature, permeabilized with 0.1% TritonX-100 and 
incubated with the primary antibody anti-pH2AX for 1hr. 
After washes, cells were incubated with the secondary 
antibody anti-rabbit Alexa Fluo-488 (Invitrogen) for 30 
min. Results were from al least 3 experiments ± SD.
Western blotting and lentiviral infections
Proteins obtained after an SDS denaturating lysis 
and sonication were transferred to nitrocellulose membrane 
and incubated with the specific primary antibodies. 
Secondary antibodies were peroxidase-conjugated goat 
anti-rabbit or anti-mouse (Sigma). Blots were developed 
with Super Signal West Dura (Pierce). For stable ATM 
down-regulation, the vector-based shRNA interference 
pLenti6/BLOCK-iT-DEST (Invitrogen) was used as 
previously described [52]. Culture supernatant obtained 
from transfected recipient 293 cells, containing viral 
particles, was recovered and used to infect MEC-1 cells.
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Abstract
Diaryldienone derivatives with accessible β-carbons show strong anti-neoplastic properties, related to their ability to
make covalent adducts with free thiols by Michael addition, and low toxicity in vivo. Accumulation of poly-
ubiquitylated proteins, activation of the unfolded protein response (UPR) and induction of cell death are universal
hallmarks of their activities. These compounds have been characterized as inhibitors of isopeptidases, a family of
cysteine-proteases, which de-conjugate ubiquitin and ubiquitin-like proteins from their targets. However, it is unclear
whether they can also react with additional proteins. In this work, we utilized the biotin-conjugated diaryldienone-
derivative named 2c, as a bait to purify novel cellular targets of these small molecules. Proteomic analyses have
unveiled that, in addition to isopeptidases, these inhibitors can form stable covalent adducts with different intracellular
proteins, thus potentially impacting on multiple functions of the cells, from cytoskeletal organization to metabolism.
These widespread activities can explain the ability of diaryldienone derivatives to efficiently trigger different cell death
pathways.
Introduction
During the past decades the identification of new small
molecule therapeutics has provided some improvements
for clinical treatments in patients with various tumors.
However, for certain cancers and particularly solid
tumors, exhibiting extreme drug resistance, the demand
of new agents is still urgent. A class of small organic
molecules, which derive from diaryldienone and contain
cross-conjugated α,β-unsaturated ketones with accessible
β-carbons, have evidenced anti-neoplastic properties and
low toxicity in different preclinical studies in vivo1–6. The
β carbon atoms of α,β-unsaturated ketones are available to
alkylate various cellular nucleophiles6–9. These small
molecules have been proposed as non-selective inhibitors
of isopeptidases, a family of enzymes that are involved in
the de-conjugation of ubiquitin and ubiquitin-like pro-
teins from different targets1,10. Indeed, cells treated with
these molecules accumulate poly-ubiquitylated proteins
in the presence of unperturbed proteasomal catalytic
activity1,2,5,10,11. Since several isopeptidases are cysteine-
proteases, they are prone to react with the α,β-unsatu-
rated ketones, thus leading to enzyme inactivation.
Importantly, these compounds cannot efficiently inhibit
the activity of other cysteine proteases, such as caspases or
cathepsins, thus indicating a certain degree of specificity9.
In vitro they can inhibit the activity of recombinant
isopeptidases8,12 and the presence of different groups, in
addition to the pharmacophore, can modulate the
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promiscuity of these compounds9,13. Hence, we refer to
them as partially-selective isopeptidase inhibitors (P-SIIs).
In cells treated with these P-SIIs, accumulation of poly-
ubiquitylated proteins is evident, in partial analogy to
bortezomib treatment2,14. Bortezomid/Carfilzomib are
inhibitors of the proteasomal catalytic chamber approved
for the use in clinic9. For this reason P-SIIs are usually
considered as alternative proteasome inhibitors. However,
when the cellular responses to the two inhibitors are
compared by gene expression profile studies, the sig-
natures are not entirely superimposable. For example, 2c,
a P-SII previously identified and characterized8, exhibits
broader effects in terms of activation of adaptive
responses. The response to oxidative stress and protein
misfolding are more pronounced in 2c compared to
bortezomib treated cells14.
The identification of the cellular targets of compounds
with therapeutic potential is an important step to improve
their activities and to understand potential side effects.
Chemical proteomics is an innovative approach to
unmask the cellular targets of small molecule ther-
apeutics. In chemical proteomics, affinity chromatography
is combined with proteomic techniques such as mass
spectrometry for the unbiased identification of protein
targets15. To identify the cellular target of P-SIIs and to
clarify their selectivity, we isolated cellular proteins bound
by 2c and analysed them by mass spectrometry. Our
approach employed a 2c-biotin conjugate as a probe to
identify in vivo the cellular targets of P-SIIs.
Results
Generation of the 2c-biotinylated probe
In order to better characterize the mechanisms
through which, diaryldienone-derivatives P-SIIs trigger
cell death and to define their cellular targets, we gener-
ated a biotinylated probe of 2c (Fig. 1). 2c is a P-SII that
we have recently synthetized and optimized for in vivo
delivery8. We initially compared the ability of 2c-biotin,
with respect to the original compound, of triggering cell
death. MEC-1 chronic lymphocytic leukemia cells were
treated for different times with the two compounds and
the appearance of cell death was evaluated by cyto-
fluorimetric analysis. Cell death was similarly induced by
2c and its biotinylated version (Fig. 1b). Next, we verified
that the death response occurred through the activation
Fig. 1 Generation and characterization of biotin-conjugated 2c. a
Structure of 2c and of the 2c-biotin conjugate. b MEC-1 cells were
treated for the indicated times with 2 µM 2c, 2c-biotin, or DMSO alone
as control. After 24 h cells were stained wit PI fixed and processed for
cytofluorimetric analysis. Mean ± SD; n = 3. c Cellular lysates of MEC-1
cells treated with 2 µM 2c or of 2c-biotin for the indicated times were
subjected to immunoblotting using the anti-Gas2 antibody. Actin
immuno-detection was used as loading control. Arrowhead points to
the caspase-cleaved product. d IMR90-E1A cells were treated with the
indicated concentrations of 2c, 2c-biotin, or DMSO as control. After 24
h cells were stained wit PI fixed and processed for cytofluorimetric
analysis. Mean ± SD; n = 3. e Cellular lysates of IMR90-E1A cells treated
with 10 µM 2c or 2c-biotin for the indicated times were subjected to
immunoblotting using the anti-ubiquitin antibody. Actin was used as
loading control. f qRT-PCR analysis of mRNA expression levels for
GLCM and HMOX1 in cells treated for the indicated hours with 10 µM
2c or 2c-biotin. Mean ± SD; n = 3. g qRT-PCR analysis of mRNA
expression levels of HSPA1A and HSPA6 in cells treated for the
indicated hours with 10 µM 2c or 2c-biotin. Mean ± SD; n = 3
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of apoptosis. Caspase-dependent processing of GAS2
was detected as early as after 3 h of treatment and was
also comparable for the two compounds (Fig. 1c)16.
Finally, we also compared the pro-death activities of 2c
and of 2c-biotin in a different cell line. IMR90-E1A cells
evidence a similar dose-dependent response, when
challenged with the two compounds (Fig. 1d). In sum-
mary, biotinylation of 2c does not perturb its ability to
trigger cell death.
Biotinylation does not alter the biological properties of 2c
Cell death induced by 2c and similar compounds is
characterized by: (i) the accumulation of poly-
ubiquitylated proteins, (ii) the induction of oxidative
stress response and (iii) of the unfolded protein response
(UPR)1,8,14,17. To verify that the presence of the biotin tag
does not influence the activation of these cellular
responses, we initially investigated the accumulation of
polyubiquitylated proteins. Figure 1e illustrates that both
2c and 2c-biotin elicit the accumulation of poly-
ubiquitylated proteins. Data suggest that the original
compound is slightly more efficient in blocking protea-
somal deubiquitylase activities. To evaluate the up-
regulations of the oxidative stress signaling, qRT-PCR
analysis was performed to measure the relative mRNA
levels of heme oxygenase HMOX1 and of GCLM, the
regulative subunit of the first rate-limiting enzyme in
glutathione biosynthesis14. The expression of both genes
was upregulated in response to both 2c and 2c-biotin. In
this instance, the mRNA levels of both genes were higher
in cells treated with the biotinylated 2c (Fig. 1f). Finally,
we also investigated the upregulation of the UPR
(Unfolded Protein Response). We previously observed
that treatment with 2c triggers the upregulation of several
chaperons, including HSPA1A and HSPA614. Figure 1g
illustrates that the mRNA levels of HSPA1A and HSPA6
were both increased in IMR90-E1A cells treated with 2c
or its biotinylated analog. However, this upregulation was
stronger in the case of 2c-biotin. In summary, our studies
indicate that 2c and 2c-biotin elicit similar adaptive cel-
lular responses, even though some specificity can be
appreciated.
Nuclear accumulation of 2c-biotin
2c and similar compounds, containing electrophilic α,β-
unsaturated carbonyl units as Michael acceptors, show
very high and selective affinity for thiol residues, in par-
ticular for cysteines. Impairment of the α, β-unsaturated
carbonyl reactivity in these compounds results in a strong
decrease of their pro-death potency6,8,18. Accordingly,
when 2c or 2c-biotin were pre-incubated with N-acetyl
cysteine (NAC) their pro-death activity was suppressed
(Fig. 2a). Hence, we used NAC as a tool to evaluate the
specificity of 2c-biotin activities in vivo.
Initially, cells were treated with biotin alone, 2c-biotin,
or 2c-biotin pre-incubated with NAC. After 6 h cells were
fixed and processed for fluorescence analysis using
streptavidin-tetramethylrhodamine (TRITC). Confocal
images were acquired and then analysed for fluorescence
intensity. Fluorescence was dramatically augmented when
cells were treated with 2c-biotin and this fluorescence was
suppressed when the compound was pre-incubated with
NAC (Fig. 2b).
Next we performed a time-course analysis to visualize
variations of the subcellular localization of 2c-biotin with
time. 2c-biotin positivity was detectable as soon as 5 min
after treatment and fluorescence was evident in the
nucleus and also in the cytoplasm (Fig. 2c). After 10 min
the intensity of fluorescence was further increased. At
later time-points (6 h) some signs of cellular stress, such
as reduced cell spreading, were evident. At this time
nuclear localization of 2c-biotin was even stronger,
whereas in the cytoplasm it accumulates in a perinuclear
area (see arrows and the higher magnification).
Pre-treatment with NAC completely abolishes the
fluorescent signals. This behavior suggests that covalent
binding of 2c to cellular thiols is necessary for its intra-
cellular accumulation or that the NAC-2c complex is not
transported through the plasma membrane. thus con-
firming that covalent binding of 2c to cellular thiols is
necessary for its intracellular accumulation (Fig. 2d).
Finally, analysis of mitotic cells suggests that 2c does not
interact with chromatin, being chromosomes in meta-
phase negative for 2c-biotin signals (Fig. 2e).
Intracellular targets of the PS-II 2c
In order to identify PS-IIs intracellular targets, IMR90-
E1A cells were treated with 2c-biotin and, after lysis,
cellular extracts were incubated with streptavidin beads.
NAC was added to verify that binding of the targets was
due to the Michael acceptor activity of the probe. To
evaluate the binding to isopeptidases, we performed
immunoblot analysis on proteins purified after 2c-biotin
mediated pull-down. For enrichment comparison, each
pull-down was incubated in parallel with antibodies
against unrelated proteins.
We initially evaluated the enrichments of USP1 and of
actin, used as negative control, with respect to their
inputs. USP1 signal was highly enriched in a NAC-
dependent manner after 2c-biotin purification (Fig. 3a). In
the case of actin, only a weak signal was observed in the 2c
pull-down. Next, we analysed the binding of 2c-biotin to
USP33 and to the serine-threonine kinase AKT, for
comparison (Fig. 3b). USP33, similarly to USP1, was
enriched after 2c-biotin pull-down in a NAC dependent
manner. Surprisingly, also AKT, after incubation with 2c-
biotin was enriched. Hence, we repeated the experiment
with USP1 using a different control, the chaperon GRP78.
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Fig. 2 Dynamics of 2c-biotin uptake and accumulation in cells. a IMR90-E1A cells were treated for 24 h as indicated. Cell death was scored as PI
positivity by cytofluorimetric analysis. 2c and 2c-biotin were used at 10 µM. NAC was 2 mM. Mean ± SD; n = 3. b IMR90-E1A cells grown on coverslips
were treated for 6 h as indicated. Cells were fixed and analysed with confocal microscope using the same parameters of acquisition. 2c-biotin was
revealed using streptavidin-TRITC. Quantitative analysis of the fluorescence intensity was performed using the Metamorph software. c IMR90-E1A cells
were treated with 2c-biotin [2 µM] for the indicated times. After fixation cells were incubated with streptavidin-TRITC. Nuclei were visualized using
Hoechst 33,342. Arrows point to cytosolic accumulation of 2c-biotin. The dotted square indicates the enlarged area. Images were obtained with an
epifluorescence microscopy. Bar 30 µm. d IMR90-E1A cells were treated with 2c-biotin [2 µM] for 2 h. When used in pre-treatment, NAC was 2 mM.
After fixation cells were incubated with streptavidin-TRITC. Nuclei were visualized using Hoechst 33,342. Images were obtained with an
epifluorescence microscopy. Bar 30 µm. e IMR90-E1A cells were treated with 2c-biotin [2 µM] for 2 h. After fixation cells were incubated with
streptavidin-TRITC. Nuclei were visualized using Hoechst 33,342. Images were obtained with an epifluorescence microscopy. A mitotic cell is shown.
Bar 50 µm. Images are shown in pseudocolors
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USP1 was again enriched, whereas GRP78 was almost
undetectable in the 2c-biotin pull-down (Fig. 3c). Since
previous studies showed that 2c inhibits the deISGlase
activity of USP18, we also evaluated the 2c pull-down for
USP188. Here as control we used HDAC4. Binding to
USP18 was evident whereas binding of HDAC4 was very
weak (Fig. 3d).
Finally, we compared the binding of 2c to UCH-L5 and
USP14, the two cysteine-deubiquitylases of the protea-
some. Their inhibition should represent the key con-
tribution to the accumulation of poly-ubiquitylated
proteins9,13. The pull-down of both DUBs was enriched
compared to Actin (Fig. 3e). Previous studies, using dif-
ferent assays, indicated that compounds similar to 2c
Fig. 3 Identification of target isopeptidases by biotin pull-down experiments. a/b/c/d/e IMR90-E1A cells were treated for 2 h with 10 µM 2c-
biotin or left untreated. 2c-botin was pre-incubated with 5 mM of NAC, as a negative control. Cellular proteins were purified by 2c-biotin pull-down
using streptavidin-agarose beads. Protein complexes were separated by SDS/PAGE and immunoblotted using the indicated antibodies. Inputs are
included for enrichment comparison. In the case of USP18 cells were pre-treated for 24 h with interferon-α. f IMR90-E1A cells were treated for 2 h
with the indicated concentrations of 2c-biotin or left untreated. As a control, 2c-biotin was pre-incubated with 5 mM NAC. Cellular proteins were
purified by 2c-biotin pull-down. Protein complexes were separated by SDS/PAGE and immunoblotted using the anti-USP14 or the anti-UCH-L5
antibodies. Inputs are included for enrichment comparison
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exhibit higher inhibition of USP14 activity compared to
UCH-L5. Hence, we compared in more detail the binding
of 2c-biotin to the two DUBs using different concentra-
tions of the inhibitor. Figure 3f confirms that in vivo 2c-
biotin binds with comparable intensity USP14 and UCH-
L5.
In summary, we demonstrated that the compound 2c
shows a certain affinity for isopeptidases. The spectrum of
enzymes recognized by 2c seems to be quite wide, thus
confirming its partial selectivity. However, USP1/
USP33 showed a higher affinity when compared to
USP18/UCH-L5/USP14. As expected, unrelated control
proteins such as Actin, HDAC4 and GRP78 showed a
weak reaction with 2c-biotin. Surprisingly, AKT can be
covalently modified by 2c-biotin.
Proteomic profiling of 2c adducts in transformed cells
The above study suggests that, in addition to iso-
peptidases, 2c might target additional proteins such as
AKT. To characterize the binding landscape of 2c, we
applied a chemical proteomic strategy. IMR90-E1A cells
were treated with 10 µM 2c-biotin for 2 h and lysed.
Biotinylated proteins were then isolated using avidin
column chromatography. As a control, the same
experiment was performed in the presence of NAC.
After SDS-PAGE separation and blue coomassie stain-
ing, lanes were divided in five parts, excised and trypsin
digested. The resulting peptides were analyzed by liquid
chromatography coupled to tandem mass spectrometry
(LC–MS/MS) and 25 proteins were successfully
identified.
Table 1 summarizes the results of such analysis. The
identified proteins fall into five different functional classes
including; metabolism (33%), proteostasis (33%), cytos-
keleton (19%), signaling (10%) and oxidative stress (5%)
(Fig. 4a). As expected some proteins were detected after
the NAC treatment as well. They could represent con-
taminants such as Tubulin and Actin. Hence, we excluded
them from the analysis. Pyruvate kinase and Eukaryotic
initiation factor 4A-1 were the two proteins detected with
the highest scores. To clarify whether the 2c-biotin
modified proteins, identified by mass-spectrometry,
reflect their relative abundance, we interrogated the pro-
tein abundance database PaxDb (http://pax-db.org.)19.
We also compared the abundance of the isopeptidases
USP1, USP14, USP18 USP33 and UCH-L5. Different cell
lines and different datasets were scrutinized20–24. Fig-
ure 4b shows the result of this analysis. As expected,
among the isopeptidases, the proteasome components
UCH-L5 and USP14 show higher abundance. Surpris-
ingly, USP14 in certain cell lines is much more abundant
than UCH-L5. USP1, USP18 and USP33 are quite rare
proteins. USP18, being interferon-inducible was almost
undetectable.
Although there is some variability among cell lines and
datasets, overall the newly identified 2c-biotin targets
represent high abundant proteins (GAPDH, ENO1, and
PKM) frequently ranking within the 5% more abundant
proteins. The only exception in the investigated cell lines
was myosin light chain 6B MYL6B.
Interestingly, among the 2c targets we identified Cofilin-
1. This protein is of particular interest since Cofilin-1 is
involved in mediating cytoskeletal changes and cell death
in response to a 2c analogous25.
Cofilin-1 phosphorylated at serine 3 interacts with 2c-
biotin
To corroborate the proteomic data, we performed 2c-
biotin pull-down experiments. We focused the analysis on
Cofilin-1, for the above-mentioned reasons. Surprisingly,
2c-biotin pull-down experiments did not evidence any
interaction with Cofilin-1 (Fig. 5a). Importantly, Cofilin-1
activities are regulated by phosphorylation of serine 3.
Therefore, we performed pull-down experiments using an
antibody recognizing Cofilin-1 when phosphorylated at
serine 3. Figure 5a indicates that 2c-biotin preferentially
reacts with the phosphorylated pool of Cofilin-1.
Cofilin-1 has 4 cysteines at positions 39, 80, 139, and
147 (Fig. 5b). Figure 5d highlights that two cysteine resi-
dues (Cys139, Cys147) are located on the surface and are
thus potentially available for the reaction with 2c. The
other two residues are partially (Cys39) and completely
buried (Cys80).
Discussion
Diaryldienone-derivatives comprise an interesting and
heterogeneous family of molecules, which selectively elicit
apoptosis in neoplastic cells. Marks of their activities are
induction of the UPR, oxidative stress, and the accumu-
lation of poly-ubiquitylated proteins. These multiple cel-
lular responses have been attributed to their ability to
function as Michael acceptors against the catalytic
cysteine of isopeptidases. Several groups have demon-
strated the ability of these molecules to impact on the
activity of these enzymes1–8,10,26. However, the presence
of additional targets has been underestimated.
To clarify this point and to better understand the
behavior of these molecules, we generated a biotinylated
version of 2c, a diaryldienone-derivative. Our studies
demonstrate that addition of biotin does not perturb the
activity of 2c. Induction of cell death, activation of cas-
pases, accumulation of poly-ubiquitylated proteins,
induction of the anti-redox and of the UPR response were
comparable between the original 2c and its biotinylated
version. Studies in vivo indicated that the compound is
rapidly up-taken by the cells. It shows a diffuse localiza-
tion and accumulates in the nuclei. Absence of punctate
staining points against an uptake through vesicle-
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Table 1 Candidate 2c-biotin targets identified by mass-spectrometry
Database/Gene Protein 2c-biotin 2c-biot/NAC
P.S. P.N. P.S P.N.
TBA1B Tubulin alpha-1A/1B chain 313 6 95 2
KPYM/PKM Pyruvate kinase PKM 184 4 nd nd
BAD96752.1 Beta actin variant 180 5 163 4
RL40 Ubiquitin-60S ribosomal protein L40 140 3 94 1
IF4A1/EIF4A1 Eukaryotic initiation factor 4A-I 128 2 nd nd
AAF36537.1/EEF1A1 glucocorticoid receptor AF-1 specific elongation factor, partial 113 3 nd nd
TBB5 Tubulin beta chain 107 2 nd nd
HS90B Heat shock protein HSP 90-beta 87 2 nd nd
COF1 Cofilin-1 83 2 nd nd
IF5A1/EIF5A1 Eukaryotic translation initiation factor 5A-1 81 1 nd nd
AAA36787.1 ubiquitin precursor, partial 78 1 nd nd
PRDX1 Peroxiredoxin-1 76 1 nd nd
MYL6B Myosin light chain 6B 66 1 nd nd
CYB5B Cytochrome b5 type B 65 1 nd nd
EAW53693.1/RACK1 guanine nucleotide binding prot., beta polypeptide 2-like 1, isoform CRA_b 65 1 nd nd
ALDOA Fructose-bisphosphate aldolase A 61 1 nd nd
MPCP/SLC25A3 Phosphate carrier protein, mitochondrial 56 1 nd nd
ENOA/ENO1 Alpha-enolase 55 1 nd nd
NDKA/NME1 Nucleoside diphosphate kinase A 51 1 nd nd
ANXA2 Annexin A2 51 1 nd nd
HSP7C/HSAP8 Heat shock cognate 71 kDa protein 50 1 nd nd
RL11/RPL11 60S ribosomal protein L11 48 1 nd nd
G3P/GAPDH Glyceraldehyde-3-phosphate dehydrogenase 46 1 nd nd
TPM1 Tropomyosin alpha-1 chain 45 1 nd nd
RS27A Ubiquitin-40S ribosomal protein S27a nd nd 47 1
P.S. indicates the Mascot protein identification score. Only proteins having one or more peptides with a score higher than 44 (identity or extensive homology, P < 0.05) were included in the protein list. P.N. indicates the
number of peptides identified and assigned to each single protein. ND (non detectable). Pull-down experiments were performed also in the presence of NAC. Proteins that were isolated in the presence of NAC are indicated



























Fig. 4 Candidate 2c-biotin targets identified by mass-spectrometry. a Identified proteins can be grouped into categories: metabolism,
proteostasis, cytoskeleton, oxidative stress, and signaling. Numbers of proteins of each category are indicated. b Relative abundance of the
isopeptidases evaluated for 2c-biotin binding by immunoblots (blue dots) in comparison with proteins identified by mass-spectrometry (green dots).
Data are presented as ranking. Data were obtained from http://pax-db.org. The selected cell lines and the original datasets are indicated
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mediated trafficking. These data are in agreement with
previous hypotheses based on studies with a structurally
related compound18.
Biotin pull-down experiments demonstrated that 2c
covalently binds several isopeptidases, in a NAC-
dependent manner and with higher affinity compared to
different control proteins. Although these studies need
further validation using different essays, we observed a
higher binding affinity for USP1 and USP33 compared to
USP14, USP18, or UCH-L5. We cannot exclude that these
differences stem from a different in vivo accessibility of
the enzymes, due to the existence of multi-protein
complexes.
Surprisingly, the serine/threonine kinase AKT was
bound with high affinity by 2c-biotin. AKT is an impor-
tant signaling enzyme, regulating survival and prolifera-
tion, whose activity is affected by G5, a 2c-like
compound25. AKT kinase activity depends on two cri-
tical residues; threonine 308 and serine 437. Treatment
with G5 promotes a transient phosphorylation of threo-
nine 308, followed by its dephosphorylation. By contrast,
serine 473 is dephosphorylated at earlier time-points.
While dephosphorylation of threonine 308 is PP2A-
dependent, serine 473 dephosphorylation is largely inde-
pendent25. Interestingly, cysteine residues 310 and 296
found in the T-loop region are critical for AKT activity
and can be subjects of bioreductive alkylation by pyr-
anonaphthoquinone lactones27,28. Hence, AKT contains
2c-addictable cysteines critical for its activity. Further
study will be necessary to understand whether the
reaction with 2c or similar compounds impairs AKT
enzymatic activity.
The mass-spec analysis confirmed that additional cel-
lular proteins are modified by 2c-biotin. These proteins
can be grouped in five major functional classes (metabo-
lism, proteostasis, cytoskeleton, signaling, and oxidative
stress).
Previous studies indicated that these compounds can be
relatively promiscuous. Actin can be addicted by 15-
Deoxy-Δ12,13-prostaglandin J2 that contains the same
unsaturated ketone pharmacophore of 2c29. The bis
(benzylidene)piperidone RA190 reacts with cysteine 88 of
the proteasome ubiquitin receptor hRpn13 and MCB-613
(4-ethyl-2,6-bis-pyridin-3-ylmethylene-cyclohexanone), a
molecule structurally similar to 2c, can stimulate steroid
receptor co-activators (SRCs) transcriptional activity7,30.
Surprisingly, isopeptidases were not identified by this
analysis. It should be noted that, among the identified 2c
targets, high abundance proteins are the foremost repre-
sented. In principle, these high abundance targets could
compete with high affinity but low abundant targets, such
as USP1 and USP33.
2c and similar molecules trigger profound changes of
cytoskeleton and cell morphology. Time-lapse experi-
ments demonstrated that, before the appearance of
apoptosis, stress fibers disassemble and cells lose adhe-
sion31. An important contribution to these cytoskeletal
changes is provided by Cofilin-1. Cofilin-1 depho-
sphorylation triggers F-actin disassembling and 2c can
favor this dephosphorylation25. Importantly, 2c-biotin
Fig. 5 Only the phosphorylated version of Cofilin-1 reacts with 2c. a IMR90-E1A cells were treated for 2 h with 10 µM 2c-biotin or left untreated.
As a control, 2c-botin was pre-incubated with 5 mM NAC. Cellular proteins were purified by 2c-biotin pull-down, next immunoblotting were
performed using the indicated antibodies. Inputs are for enrichment comparison. b Primary sequence of human Cofilin-1. Cysteine residues are
highlighted in yellow and serine 3 in red. c Cartoon structure of Cofilin-1 (PDB: 1Q8G) showing the phosphorylation site (Ser3) in red and the four
cysteine residues in yellow. d Protein surface superimposed to the cartoon representation, with the same color code. The distance between Ser3 and
the available cysteines is 26 Å (Cys139) and 34 Å (Cys147). Images were obtained with the PyMOL Molecular Graphics System, Schrödinger, LLC
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preferentially modifies the phosphorylated pool of Cofilin-
1. This observation suggests that 2c could impact F-actin
dynamic directly, by hijacking Cofilin-1 functions. Cofilin
dimers/oligomers exhibit bundling activities and dimer-
ization occurs via the formation of intermolecular dis-
ulfide bridges involving Cys (39) and, probably, Cys (147)
of adjacent Cofilin units. Indeed, these cysteines can react
with cucurbitacins, triterpenoid natural compounds32.
Smilarly, by reacting with the cysteines of Cofilin, 2c
might impair dimerization and thus impact directly on F-
actin severing33–35. Cysteine residues (Cys139, Cys147)
are located on the surface and are thus potentially avail-
able for the reaction with 2c. Interestingly, the distance
between Ser3 and these cysteines is 26 Å (Cys139) and 34
Å (Cys147).
In summary, our studies demonstrate that
diaryldienone-derivatives can be addicted to several cel-
lular proteins in addition to isopeptidases. The combina-
tion of different targets can elicit multiple stresses, which
are not manageable in neoplastic cells, thus explaining
their efficient anti-tumor activity observed in vivo.
Materials and methods
Reagents and antibodies
Chemicals used were: bortezomib (LC Laboratories),
Propidium Iodide and N-acetylcysteine (Sigma Aldrich).
Primary antibodies used were: anti-Gas236 anti-actin
(Sigma/Aldrich) anti-USP137 anti-USP33 (Millipore)
anti-AKT (Cell Signaling) anti-UCH-L5 (Abcam), anti-
USP1838 anti-HDAC439 anti-MEF2D (BD Bioscience),
anti-GRP78, anti-USP14, anti-Cofilin-1, anti-pCofilin-1
(Santa Cruz Biotechnologies).
Synthesis of the biotinylated version of 2c
Briefly, the biotinylated derivative of 2c was obtained by
the insertion of a cadaverine linker between biotin and 2c.
To this end, biotin was first used to acylate one of the
amino groups of cadaverine, and then the resulting adduct
was linked to 2c via a carbamate linkage obtained by
reaction with 2c-OSu. Products and intermediates were
characterized by Electrospray Ionization mass spectro-
metry (ESI-MS) performed on an Esquire 4000 (Bruker
Daltonics) spectrometer and by 1H and 13C NMR (Varian,
500MHz). Full details are reported in the supplementary
materials.
Culture conditions, fluorescence microscopy, and cell
death analysis
MEC-1 cells were grown in RPMI medium whereas
IMR90-E1A cells were cultured in DMEM. Mediums were
supplemented with heated inactivated fetal calf serum
(Sigma Aldrich), penicillin (100 U/mL), glutamine (2
mmol/L), and streptomycin (100 μg/mL). Fluorescence
microscopy was performed as previously described1.
Briefly, cells were fixed in 3% paraformaldehyde, per-
meabilized with 1% Triton-X100 and incubated with
TRITC streptavidin (Molecular probes). For the quanti-
fication of cell death, cells were re-suspended in 500 μL of
PBS and stained with propidium iodide (PI). Fluorescence
was determined with a FACScan™ (Beckman Dickinson).
IFN-α2a (1000 units/mL; Jena Bioscience) was used as
previously described40.
2c-Biotin pull-down and immunoblotting
For pull-down experiments 4.5× 105 IMR90-E1A cells
were treated with 10 µM 2c-biotin for 2 h. When used, N-
acetylcysteine (NAC) was 5 mM. Cell lysis was performed
in lysis buffer (PBS, 2%SDS, 5 mM DTT). Proteins
obtained after an SDS denaturating lysis and sonication,
were incubated with streptavidin-agarose beads (GE
Healthcare). After several washes in lysis buffer, they were
eluted after boiling in sample buffer. Next SDS/PAGE
electrophoresis was performed and proteins were trans-
ferred to nitrocellulose membrane and incubated with the
specific primary antibodies. Secondary antibodies were
peroxidase-conjugated goat anti-rabbit or anti-mouse
(Sigma/Aldrich). Blots were developed with Super Signal
West Dura (Pierce).
RNA extraction and qRT-PCR analysis
RNA was extracted using Tri-Reagent (Molecular
Research Center) and retrotranscribed by using 100U of
Moloney murine leukemia virus reverse transcriptase
(Invitrogen). The primer sequences used are available
upon request. Quantitative reverse transcription-PCR
(qRT-PCR) analyses were performed using Bio-Rad
CFX96 and SYBR Green technology. HPRT and
GAPDH were used as normalizer genes. All reactions
were done in triplicate. Data were from al least three
experiments ±SD.
Proteomic analysis
2c–biotin pull down samples were separated by SDS—
PAGE and the gel stained by Coomassie blue. The lanes
corresponding to 2c—biotin and 2c—biotin plus NAC
were excised and divided into five parts. Proteins were in
gel digested and identified by LC-MS/MS analysis essen-
tially as previously described using a 1200 Series Nano
HPLC (Agilent)41. Only proteins having one or more
peptides with a score higher than 44 (identity or extensive
homology, P< 0.05) were included in the protein list.
Keratins and Streptavidin were excluded from the iden-
tified proteins. Protein have been listed according to the
Mascot protein score42,43.
Acknowledgements
This work was supported by grant from Regione Friuli-Venezia Giulia POR FESR
2014-2020 “ATENA” and AIRC (Associazione Italiana per la Ricerca sul Cancro)
CB
Ciotti et al. Cell Death and Disease  (2018) 9:184 Page 10 of 11
Official journal of the Cell Death Differentiation Association
Author details
1Department of Medicine, Università degli Studi di Udine, P.le Kolbe 4, 33100
Udine, Italy. 2Department of Life Sciences, Università degli Studi di Trieste, Via L.
Giorgieri 5, 34127 Trieste, Italy. 3Dipartimento di Scienze Chimiche e
Farmaceutiche, Universita degli Studi di Trieste, Via Giorgieri 1, 34127 Trieste,
Italy
Conflict of interest
The authors declare that they have no conflict of interest.
Supplementary Information accompanies this paper at https://doi.org/
10.1038/s41419-017-0259-1.
Received: 13 October 2017 Revised: 7 December 2017 Accepted: 22
December 2017
References
1. Aleo, E., Henderson, C. J., Fontanini, A., Solazzo, B. & Brancolini, C. Identification
of new compounds that trigger apoptosome-independent caspase activation
and apoptosis. Cancer Res. 66, 9235–9244 (2006).
2. D’Arcy, P. et al. Inhibition of proteasome deubiquitinating activity as a new
cancer therapy. Nat. Med. 17, 1636–1640 (2011).
3. Coughlin, K. et al. Small-molecule RA-9 inhibits proteasome-associated DUBs
and ovarian cancer in vitro and in vivo via exacerbating unfolded protein
responses. Clin. Cancer Res. 20, 3174–3186 (2014).
4. Issaenko, O. A. & Amerik, A. Y. Chalcone-based small-molecule inhibitors
attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell
Cycle 11, 1804–1817 (2012).
5. Shukla, N. et al. Proteasome addiction defined in ewing sarcoma is effectively
targeted by a novel class of 19S proteasome inhibitors. Cancer Res. 76,
4525–4534 (2016).
6. Karki, S. S. et al. 3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piper-
idones: a novel class of potent tumor-selective cytotoxins. J. Med. Chem. 59,
763–769 (2016).
7. Anchoori, R. K. et al. A bis-benzylidine piperidone targeting proteasome ubi-
quitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell 24,
791–805 (2013).
8. Cersosimo, U. et al. Synthesis, characterization, and optimization for in vivo
delivery of a nonselective isopeptidase inhibitor as new antineoplastic agent.
J. Med. Chem. 58, 1691–1704 (2015).
9. Selvaraju, K. et al. Inhibition of proteasome deubiquitinase activity: a strategy
to overcome resistance to conventional proteasome inhibitors? Drug. Resist.
Updates 21-22, 20–29 (2015).
10. Mullally, J. E. & Fitzpatrick, F. A. Pharmacophore model for novel inhibitors of
ubiquitin isopeptidases that induce p53-independent cell death. Mol. Phar-
macol. 62, 351–358 (2002).
11. Tian, Z. et al. A novel small molecule inhibitor of deubiquitylating enzyme
USP14 and UCH-L5 induces apoptosis in multiple myeloma and overcomes
bortezomib resistance. Blood 123, 706–716 (2014).
12. Nicholson, B. et al. Characterization of ubiquitin and ubiquitin-like-protein
isopeptidase activities. Protein Sci. 17, 1035–1043 (2008).
13. Wang, X. et al. The proteasome deubiquitinase inhibitor VLX1570 shows
selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple
myeloma cells. Sci. Rep. 6, 26979, https://doi.org/10.1038/srep26979 (2016).
14. Tomasella, A. et al. The isopeptidase inhibitor 2cPE triggers proteotoxic stress
and ATM activation in chronic lymphocytic leukemia cells. Oncotarget 7,
45429–45443 (2016).
15. Karasawa, T., Wang, Q., David, L. L. & Steyger, P. S. CLIMP-63 is a gentamicin-
binding protein that is involved in drug-induced cytotoxicity. Cell Death Dis. 1,
e102 (2010).
16. Brancolini, C., Benedetti, M. & Schneider, C. Microfilament reorganization
during apoptosis: the role of Gas2, a possible substrate for ICE-like proteases.
Embo J. 14, 5179–5190 (1995).
17. Oh, B. M. et al. Cystatin SN inhibits auranofin-induced cell death by autophagic
induction and ROS regulation via glutathione reductase activity in colorectal
cancer. Cell Death Dis. 8, e3053, https://doi.org/10.1038/cddis.2017.446 (2017).
18. Wang, X. et al. The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and
elicits rapid commitment to cell death. Mol. Pharmacol. 85, 932–945 (2014).
19. Wang, M. et al. PaxDb, a database of protein abundance averages across all
three domains of life. Mol. Cell Proteom. 11, 492–500 (2012).
20. Nagaraj, N. et al. Deep proteome and transcriptome mapping of a human
cancer cell line. Mol. Syst. Biol. 7, 548 (2011).
21. Balbin, O. A. et al. Reconstructing targetable pathways in lung cancer by
integrating diverse omics data. Nat. Commun. 4, 2617 (2013).
22. Geiger, T., Wehner, A., Schaab, C., Cox, J. & Mann, M. Comparative proteomic
analysis of eleven common cell lines reveals ubiquitous but varying expression
of most proteins. Mol. Cell Proteom. 11, M111.014050 (2012).
23. Kim, M. S. et al. Heterogeneity of pancreatic cancer metastases in a single
patient revealed by quantitative proteomics. Mol. Cell Proteom. 1311,
2803–2811 (2014).
24. Schmidt, A. et al. Absolute quantification of microbial proteomes at different
states by directed mass spectrometry. Mol. Syst. Biol. 7, 510 (2011).
25. Tomasella, A., Blangy, A. & Brancolini, C. A receptor-interacting protein 1 (RIP1)-
independent necrotic death under the control of protein phosphatase PP2A
that involves the reorganization of actin cytoskeleton and the action of cofilin-
1. J. Biol. Chem. 289, 25699–25710 (2014).
26. Wang, S. et al. Inhibition of the deubiquitinase USP5 leads to c-Maf protein
degradation and myeloma cell apoptosis. Cell Death Dis. 8, e3058 (2017).
27. Salaski, E. J. et al. Pyranonaphthoquinone lactones: a new class of AKT selective
kinase inhibitors alkylate a regulatory loop cysteine. J. Med. Chem. 52,
2181–2184 (2009).
28. Toral-Barza, L. et al. Discovery of lactoquinomycin and related pyr-
anonaphthoquinones as potent and allosteric inhibitors of AKT/PKB:
mechanistic involvement of AKT catalytic activation loop cysteines. Mol.
Cancer Ther. 6, 3028–3828 (2007).
29. Aldini, G. et al. Identification of actin as a 15-deoxy-Delta12,14-prostaglandin J2
target in neuroblastoma cells: mass spectrometric, computational, and func-
tional approaches to investigate the effect on cytoskeletal derangement.
Biochemistry 46, 2707–2718 (2007).
30. Wang, L. et al. Characterization of a steroid receptor coactivator small mole-
cule stimulator that overstimulates cancer cells and leads to cell stress and
death. Cancer Cell 28, 240–252 (2015).
31. Fontanini, A. et al. The isopeptidase inhibitor G5 triggers a caspase-
independent necrotic death in cells resistant to apoptosis: a comparative
study with the proteasome inhibitor bortezomib. J. Biol. Chem. 284,
8369–8381 (2009).
32. Gabrielsen, M. et al. Cucurbitacin covalent bonding to cysteine thiols: the
filamentous-actin severing protein Cofilin1 as an exemplary target. Cell
Commun. Signal. 11, 58 (2014).
33. Bernstein, B. W. & Bamburg, J. R. ADF/cofilin: a functional node in cell biology.
Trends Cell Biol. 20, 187–195 (2010).
34. Pfannstiel, J. et al. Human cofilin forms oligomers exhibiting actin bundling
activity. J. Biol. Chem. 276, 49476–49484 (2001).
35. Cameron, J. M. et al. Polarized cell motility induces hydrogen peroxide to
inhibit cofilin via cysteine oxidation. Curr. Biol. 25, 1520–1525 (2015).
36. Brancolini, C. & Bottega, S. Schneider C. Gas2, a growth arrest-specific protein,
is a component of the microfilament network system. J. Cell Biol. 117,
1251–1261 (1992).
37. Cataldo, F. et al. CAPNS1 regulates USP1 stability and maintenance of genome
integrity. Mol. Cell. Biol. 33, 2485–2496 (2013).
38. Potu, H., Sgorbissa, A. & Brancolini, C. Identification of USP18 as an important
regulator of the susceptibility to IFN-alpha and drug-induced apoptosis.
Cancer Res. 70, 655–665 (2010).
39. Di Giorgio, E. et al. The co-existence of transcriptional activator and tran-
scriptional repressor MEF2 complexes influences tumor aggressiveness. PLoS
Genet. 13, e1006752 (2017).
40. Sgorbissa, A., Tomasella, A., Potu, H., Manini, I. & Brancolini, C. Type I IFNs
signaling and apoptosis resistance in glioblastoma cells. Apoptosis 16,
1229–1244 (2011).
41. Sgarra, R. et al. Interaction proteomics of the HMGA chromatin architectural
factors. Proteomics 8, 4721–4732 (2008).
42. Pope, B. J., Zierler-Gould, K. M., Kühne, R., Weeds, A. G. & Ball, L. J. Solution
structure of human cofilin: actin binding, pH sensitivity, and relationship to
actin-depolymerizing factor. J. Biol. Chem. 279, 4840–4848 (2004).
43. Mizuno, K. Signaling mechanisms and functional roles of cofilin phosphor-
ylation and dephosphorylation. Cell. Signal. 25, 457–469 (2013).
Ciotti et al. Cell Death and Disease  (2018) 9:184 Page 11 of 11
Official journal of the Cell Death Differentiation Association
